uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q22.368 | Q22 | What is Levoxyl? | Levoxyl, also known generically as Levothyroxine Sodium, was approved by the FDA in 2000 to treat thyroid carcinoma, hypothyroidism, differentiated thyroid carcinoma, thyroid cancer, and congenital hypothyroidism. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%levoxyl%" OR LOWER(tradeNames_string) LIKE "%levoxyl%" OR LOWER(drugSynonyms_string) LIKE "%levoxyl%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5964', 'tradeNames_string': 'Eltroxin, Ermeza, Euthyrox, Evotrox, L-thyroxine henning, Levo-t, Levolet, Levothroid, Levothyroid, Levothyroxine sodium, Levoxine, Levoxyl, Novothyrox, Soloxine, Synthroid, Thyquidity, Thyro-tabs, Thyrol L, Thyroxine, Tirosint, Tirosint-sol, Unithroid', 'drugName': 'Levothyroxine Sodium', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Thyroid hormone receptor agonist', 'linkedDiseasesDrug_string': 'Congenital Hypothyroidism (MONDO_0018612), Pain (EFO_0003843), Thyroid Carcinoma (EFO_0002892), Thyroid Cancer (MONDO_0002108), Bipolar Disorder (MONDO_0004985), Hypothyroidism (EFO_0004705), Differentiated Thyroid Carcinoma (EFO_1002017)', 'newLinkedTargets_string': 'THRA (ENSG00000126351), THRB (ENSG00000151090)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2000, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.624 | Q22 | What is Tepmetko? | Tepmetko, also known generically as Tepotinib Hydrochloride, was approved by the FDA in 2021 to treat non-small cell lung carcinoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tepmetko%" OR LOWER(tradeNames_string) LIKE "%tepmetko%" OR LOWER(drugSynonyms_string) LIKE "%tepmetko%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1908', 'tradeNames_string': 'Tepmetko', 'drugName': 'Tepotinib Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Hepatocyte growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Non-Small Cell Lung Carcinoma (EFO_0003060), Neoplasm (EFO_0000616)', 'newLinkedTargets_string': 'MET (ENSG00000105976)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.585 | Q22 | What is Janumet Xr? | Janumet Xr, also known generically as Sitagliptin Phosphate, was approved by the FDA in 2006 to treat myocardial infarction, stroke, type 2 diabetes mellitus, and hyperlipidemia. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%janumet xr%" OR LOWER(tradeNames_string) LIKE "%janumet xr%" OR LOWER(drugSynonyms_string) LIKE "%janumet xr%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2411', 'tradeNames_string': 'Janumet Xr, Januvia', 'drugName': 'Sitagliptin Phosphate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Dipeptidyl peptidase IV inhibitor', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Hyperlipidemia (MONDO_0021187), Stroke (EFO_0000712), Myocardial Infarction (EFO_0000612), Renal Insufficiency (HP_0000083), Type 2 Diabetes Mellitus (MONDO_0005148)', 'newLinkedTargets_string': 'DPP4 (ENSG00000197635)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2006, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.235 | Q22 | What is Esomeprazole Magnesium? | The drug Esomeprazole Magnesium was approved by the FDA in 2001 to treat Esophagitis, rheumatoid arthritis, ankylosing spondylitis, gastroesophageal reflux disease, duodenal ulcer, Zollinger-Ellison Syndrome, gastric ulcer, and osteoarthritis. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%esomeprazole magnesium%" OR LOWER(tradeNames_string) LIKE "%esomeprazole magnesium%" OR LOWER(drugSynonyms_string) LIKE "%esomeprazole magnesium%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4440', 'tradeNames_string': 'Esomeprazole magnesium, Nexium, Nexium 24hr', 'drugName': 'Esomeprazole Magnesium', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Potassium-transporting ATPase inhibitor', 'linkedDiseasesDrug_string': 'Esophagitis (HP_0100633), Osteoarthritis (MONDO_0005178), Ankylosing Spondylitis (EFO_0003898), Type 2 Diabetes Mellitus (MONDO_0005148), Gastric Ulcer (EFO_0009454), Duodenal Ulcer (EFO_0004607), Rheumatoid Arthritis (EFO_0000685), Chronic Pancreatitis (EFO_0000342), Zollinger-Ellison Syndrome (EFO_0007549), Helicobacter Pylori Infectious Disease (EFO_1000961), Gastroesophageal Reflux Disease (EFO_0003948), Peptic Ulcer Disease (MONDO_0004247)', 'newLinkedTargets_string': 'ATP4A (ENSG00000105675), ATP4B (ENSG00000186009)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2001, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.342 | Q22 | What is Vyzulta? | Vyzulta, also known generically as Latanoprostene Bunod, was approved by the FDA in 2017 to treat glaucoma, open-angle glaucoma, and ocular hypertension. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vyzulta%" OR LOWER(tradeNames_string) LIKE "%vyzulta%" OR LOWER(drugSynonyms_string) LIKE "%vyzulta%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2312', 'tradeNames_string': 'Vesneo, Vyzulta', 'drugName': 'Latanoprostene Bunod', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Prostanoid FP receptor agonist', 'linkedDiseasesDrug_string': 'Open-Angle Glaucoma (EFO_0004190), Ocular Hypertension (EFO_1001069), Glaucoma (MONDO_0005041)', 'newLinkedTargets_string': 'PTGFR (ENSG00000122420)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2017, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.662 | Q22 | What is Travatan Z? | Travatan Z, also known generically as Travoprost, was approved by the FDA in 2001 to treat glaucoma, open-angle glaucoma, and ocular hypertension. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%travatan z%" OR LOWER(tradeNames_string) LIKE "%travatan z%" OR LOWER(drugSynonyms_string) LIKE "%travatan z%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3870', 'tradeNames_string': 'Izba, Travatan, Travatan z, Travoprost', 'drugName': 'Travoprost', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Prostanoid FP receptor agonist', 'linkedDiseasesDrug_string': 'Exfoliation Syndrome (EFO_0004235), Open-Angle Glaucoma (EFO_0004190), Ocular Hypertension (EFO_1001069), Glaucoma (MONDO_0005041)', 'newLinkedTargets_string': 'PTGFR (ENSG00000122420)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2001, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.166 | Q22 | What is Pradaxa? | Pradaxa, also known generically as Dabigatran Etexilate Mesylate, was approved by the FDA in 2010 to treat atrial fibrillation, stroke, and deep vein thrombosis. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pradaxa%" OR LOWER(tradeNames_string) LIKE "%pradaxa%" OR LOWER(drugSynonyms_string) LIKE "%pradaxa%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2486', 'tradeNames_string': 'Pradaxa', 'drugName': 'Dabigatran', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Thrombin inhibitor', 'linkedDiseasesDrug_string': 'Hematoma (EFO_0010680), Ischemic Stroke (HP_0002140), Respiratory Syncytial Virus Infection (EFO_1001413), Hemorrhage (MP_0001914), Stroke (EFO_0000712), Cadasil (Orphanet_136), Venous Thromboembolism (EFO_0004286), Thromboembolism (HP_0001907), Injury (EFO_0000546), Renal Insufficiency (HP_0000083), Atrial Fibrillation (EFO_0000275)', 'newLinkedTargets_string': 'F2 (ENSG00000180210)', 'maxClinicalTrialPhase': 3, 'yearOfFirstApproval': 0, 'drugIsApproved': False}, {'UUID': 'DrugGeneTargets_v2_5711', 'tradeNames_string': 'Pradaxa', 'drugName': 'Dabigatran Etexilate Mesylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Thrombin inhibitor', 'linkedDiseasesDrug_string': 'Acute Pancreatitis (EFO_1000652), Stroke (EFO_0000712), Deep Vein Thrombosis (EFO_0003907), Atrial Fibrillation (EFO_0000275)', 'newLinkedTargets_string': 'F2 (ENSG00000180210)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2010, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_952', 'tradeNames_string': 'Pradaxa', 'drugName': 'Dabigatran Etexilate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Thrombin inhibitor', 'linkedDiseasesDrug_string': 'Recurrent Thrombophlebitis (HP_0004419), Chronic Kidney Disease (EFO_0003884), Coronary Artery Disease (EFO_0001645), Abnormality Of Blood And Blood-Forming Tissues (HP_0001871), Stroke (EFO_0000712), Deep Vein Thrombosis (EFO_0003907), Venous Thromboembolism (EFO_0004286), Non-Alcoholic Fatty Liver Disease (EFO_0003095), Thromboembolism (HP_0001907), Venous Thrombosis (HP_0004936), Thrombotic Disease (MONDO_0000831), Renal Insufficiency (HP_0000083), Acute Pancreatitis (EFO_1000652), Prostate Adenocarcinoma (EFO_0000673), Atrial Fibrillation (EFO_0000275)', 'newLinkedTargets_string': 'F2 (ENSG00000180210)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2010, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.290 | Q22 | What is Cuvposa? | Cuvposa, also known generically as Glycopyrrolate, was approved by the FDA in 1961 to treat Airway obstruction and gastrointestinal disease. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cuvposa%" OR LOWER(tradeNames_string) LIKE "%cuvposa%" OR LOWER(drugSynonyms_string) LIKE "%cuvposa%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1138', 'tradeNames_string': 'Cuvposa, Dartisla odt, Glycopyrrolate, Glyrx-pf, Lonhala magnair kit, Robinul, Robinul forte, Robinul fte, Seebri, Sialanar', 'drugName': 'Glycopyrrolate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Muscarinic acetylcholine receptor M3 antagonist', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979), Burn (EFO_0009516), Drooling (HP_0002307), Chronic Obstructive Pulmonary Disease (EFO_0000341), Kidney Disease (EFO_0003086), Airway Obstruction (HP_0006536), Depressive Disorder (MONDO_0002050), Hyperhidrosis (HP_0000975), Gastrointestinal Disease (EFO_0010282)', 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1961, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1139', 'tradeNames_string': 'Cuvposa, Dartisla odt, Glycopyrrolate, Glyrx-pf, Lonhala magnair kit, Robinul, Robinul forte, Robinul fte, Seebri, Sialanar', 'drugName': 'Glycopyrrolate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Muscarinic acetylcholine receptor M1 antagonist', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979), Burn (EFO_0009516), Drooling (HP_0002307), Chronic Obstructive Pulmonary Disease (EFO_0000341), Kidney Disease (EFO_0003086), Airway Obstruction (HP_0006536), Depressive Disorder (MONDO_0002050), Hyperhidrosis (HP_0000975), Gastrointestinal Disease (EFO_0010282)', 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1961, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.619 | Q22 | What is Gattex Kit? | Gattex Kit, also known generically as Teduglutide, was approved by the FDA in 2012 to treat short bowel syndrome and primary short bowel syndrome. It is a protein therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%gattex kit%" OR LOWER(tradeNames_string) LIKE "%gattex kit%" OR LOWER(drugSynonyms_string) LIKE "%gattex kit%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1614', 'tradeNames_string': 'Gattex kit', 'drugName': 'Teduglutide', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucagon-like peptide 2 receptor agonist', 'linkedDiseasesDrug_string': "Hyperlipidemia (MONDO_0021187), Hiv Infection (EFO_0000764), Crohn'S Disease (EFO_0000384), Liver Disease (EFO_0001421), Graft Versus Host Disease (MONDO_0013730), Kidney Disease (EFO_0003086), Primary Short Bowel Syndrome (MONDO_0018241), Malnutrition (EFO_0008572), Short Bowel Syndrome (MONDO_0015183)", 'newLinkedTargets_string': 'GLP2R (ENSG00000065325)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.524 | Q22 | What is Zypitamag? | Zypitamag, also known generically as Pitavastatin Magnesium, was approved by the FDA in 2017 to treat Abnormal circulating lipid concentration and hyperlipidemia. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%zypitamag%" OR LOWER(tradeNames_string) LIKE "%zypitamag%" OR LOWER(drugSynonyms_string) LIKE "%zypitamag%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1773', 'tradeNames_string': 'Zypitamag', 'drugName': 'Pitavastatin Magnesium', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'HMG-CoA reductase inhibitor', 'linkedDiseasesDrug_string': 'Abnormal Circulating Lipid Concentration (HP_0003119), Hyperlipidemia (MONDO_0021187)', 'newLinkedTargets_string': 'HMGCR (ENSG00000113161)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2017, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.470 | Q22 | What is Bylvay? | Bylvay, also known generically as Odevixibat, was approved by the FDA in 2021 to treat Pruritus and familial intrahepatic cholestasis. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bylvay%" OR LOWER(tradeNames_string) LIKE "%bylvay%" OR LOWER(drugSynonyms_string) LIKE "%bylvay%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1281', 'tradeNames_string': 'Bylvay', 'drugName': 'Odevixibat', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Ileal bile acid transporter inhibitor', 'linkedDiseasesDrug_string': 'Biliary Atresia (MONDO_0008867), Biliary Liver Cirrhosis (EFO_0004267), Alagille Syndrome (MONDO_0007318), Non-Alcoholic Steatohepatitis (EFO_1001249), Familial Intrahepatic Cholestasis (MONDO_0017290), Cholestasis (MONDO_0001751), Pruritus (HP_0000989)', 'newLinkedTargets_string': 'SLC10A2 (ENSG00000125255)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.281 | Q22 | What is Horizant? | Horizant, also known generically as Gabapentin Enacarbil, was approved by the FDA in 2011 to treat epilepsy, restless legs syndrome, and neuralgia. It is a small molecule therapy that acts as a(n) modulator. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%horizant%" OR LOWER(tradeNames_string) LIKE "%horizant%" OR LOWER(drugSynonyms_string) LIKE "%horizant%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4133', 'tradeNames_string': 'Horizant', 'drugName': 'Gabapentin Enacarbil', 'drugMolecularType': 'Small molecule', 'drugActionType': 'modulator', 'drugMechanismOfAction': 'Voltage-gated calcium channel modulator', 'linkedDiseasesDrug_string': 'Diabetic Neuropathy (EFO_1000783), Migraine Disorder (MONDO_0005277), Kidney Disease (EFO_0003086), Epilepsy (EFO_0000474), Neuralgia (EFO_0009430), Alcohol Dependence (MONDO_0007079), Restless Legs Syndrome (EFO_0004270)', 'newLinkedTargets_string': 'CACNA1H (ENSG00000196557), CACNA2D1 (ENSG00000153956), CACNA1C (ENSG00000151067), CACNA2D3 (ENSG00000157445), CACNA1S (ENSG00000081248), CACNA2D2 (ENSG00000007402), CACNA1D (ENSG00000157388), CACNA1A (ENSG00000141837), CACNA1B (ENSG00000148408), CACNA1G (ENSG00000006283), CACNA2D4 (ENSG00000151062), CACNA1I (ENSG00000100346), CACNA1F (ENSG00000102001), CACNA1E (ENSG00000198216), CACNB4 (ENSG00000182389), CACNB2 (ENSG00000165995), CACNB1 (ENSG00000067191), CACNB3 (ENSG00000167535), CACNG7 (ENSG00000105605), CACNG5 (ENSG00000075429), CACNG2 (ENSG00000166862), CACNG4 (ENSG00000075461), CACNG8 (ENSG00000142408), CACNG3 (ENSG00000006116), CACNG6 (ENSG00000130433), CACNG1 (ENSG00000108878)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2011, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.414 | Q22 | What is Adhansia Xr? | Adhansia Xr, also known generically as Methylphenidate Hydrochloride, was approved by the FDA in 1955 to treat attention deficit hyperactivity disorder. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%adhansia xr%" OR LOWER(tradeNames_string) LIKE "%adhansia xr%" OR LOWER(drugSynonyms_string) LIKE "%adhansia xr%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_845', 'tradeNames_string': 'Adhansia xr, Aptensio xr, Concerta, Delmosart, Equasym, Equasym xl, Jornay pm, Matoride xl, Medikinet, Medikinet xl, Metadate cd, Metadate er, Methylin, Methylin er, Methylphenidate hydrochloride, Quillichew er, Quillivant xr, Relexxii, Ritalin, Ritalin la, Ritalin sr, Ritalin-sr, Tranquilyn, Xenidate xl', 'drugName': 'Methylphenidate Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Norepinephrine transporter inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Sleep Disorder (EFO_0008568), Conduct Disorder (EFO_0004216), Nicotine Dependence (EFO_0003768), Chronic Progressive Multiple Sclerosis (EFO_0003840), Attention Deficit Hyperactivity Disorder (EFO_0003888), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Fatigue (HP_0012378), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090), Childhood Apraxia Of Speech (MONDO_0011184)', 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1955, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_846', 'tradeNames_string': 'Adhansia xr, Aptensio xr, Concerta, Delmosart, Equasym, Equasym xl, Jornay pm, Matoride xl, Medikinet, Medikinet xl, Metadate cd, Metadate er, Methylin, Methylin er, Methylphenidate hydrochloride, Quillichew er, Quillivant xr, Relexxii, Ritalin, Ritalin la, Ritalin sr, Ritalin-sr, Tranquilyn, Xenidate xl', 'drugName': 'Methylphenidate Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Dopamine transporter inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Sleep Disorder (EFO_0008568), Conduct Disorder (EFO_0004216), Nicotine Dependence (EFO_0003768), Chronic Progressive Multiple Sclerosis (EFO_0003840), Attention Deficit Hyperactivity Disorder (EFO_0003888), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Fatigue (HP_0012378), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090), Childhood Apraxia Of Speech (MONDO_0011184)', 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1955, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.107 | Q22 | What is Xaracoll? | Xaracoll, also known generically as Bupivacaine Hydrochloride, was approved by the FDA in 1972 to treat pain. It is a small molecule therapy that acts as a(n) blocker. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%xaracoll%" OR LOWER(tradeNames_string) LIKE "%xaracoll%" OR LOWER(drugSynonyms_string) LIKE "%xaracoll%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1687', 'tradeNames_string': 'Bupivac hcl, Bupivacaine hydrochloride, Bupivacaine hydrochloride kit, Bupivacaine hydrochloride preservative free, Marcain, Marcaine, Marcaine hydrochloride, Marcaine hydrochloride preservative free, Sensorcaine, Xaracoll', 'drugName': 'Bupivacaine Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Sodium channel protein type IV alpha subunit blocker', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Osteoarthritis (MONDO_0005178), Hiv Infection (EFO_0000764), Inguinal Hernia (HP_0000023), Hemorrhoid (EFO_0009552), Chronic Pain (HP_0012532), Pain (EFO_0003843), Radiculopathy (MONDO_0002959), Peritoneum Cancer (MONDO_0002087), Hallux Valgus (HP_0001822), Cleft Palate (HP_0000175), Injury (EFO_0000546), Hot Flashes (HP_0031217), Parathyroid Adenoma (EFO_1001087)', 'newLinkedTargets_string': 'SCN4A (ENSG00000007314)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1972, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.117 | Q22 | What is Enstilar? | Enstilar, also known generically as Calcipotriene, was approved by the FDA in 1993 to treat psoriasis and psoriasis vulgaris. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%enstilar%" OR LOWER(tradeNames_string) LIKE "%enstilar%" OR LOWER(drugSynonyms_string) LIKE "%enstilar%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5049', 'tradeNames_string': 'Calcipotriene, Dovobet, Dovonex, Enstilar, Sorilux, Xamiol', 'drugName': 'Calcipotriene', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Vitamin D receptor agonist', 'linkedDiseasesDrug_string': 'Eczema (HP_0000964), Localised Scleroderma (EFO_1001361), Vitiligo (EFO_0004208), Psoriasis (EFO_0000676), Squamous Cell Carcinoma (EFO_0000707), Radiodermatitis (MONDO_0043771), Atopic Eczema (EFO_0000274), Actinic Keratosis (EFO_0002496), Skin Disease (EFO_0000701), Acne (EFO_0003894), Scleroderma (EFO_1001993), Psoriasis Vulgaris (EFO_1001494)', 'newLinkedTargets_string': 'VDR (ENSG00000111424)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1993, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.634 | Q22 | What is Aveed? | Aveed, also known generically as Testosterone Undecanoate, was approved by the FDA in 2014 to treat neoplasm, Klinefelter's syndrome, orchitis, hypogonadism, and hypogonadotropic hypogonadism. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%aveed%" OR LOWER(tradeNames_string) LIKE "%aveed%" OR LOWER(drugSynonyms_string) LIKE "%aveed%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_939', 'tradeNames_string': 'Andriol, Aveed, Jatenzo, Kyzatrex, Nebido, Restandol, Restandol testocap, Tlando, Undestor', 'drugName': 'Testosterone Undecanoate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Androgen Receptor agonist', 'linkedDiseasesDrug_string': "Hypogonadism (MONDO_0002146), Coronary Artery Disease (EFO_0001645), Prostate Cancer (MONDO_0008315), Neoplasm (EFO_0000616), Respiratory Failure (EFO_0009686), Renal Cell Carcinoma (EFO_0000681), Klinefelter'S Syndrome (EFO_1001006), Hypogonadotropic Hypogonadism (MONDO_0018555), Aging (GO_0007568), Malnutrition (EFO_0008572), Sexual Dysfunction (EFO_0004714), Spinal Cord Injury (EFO_1001919), Orchitis (EFO_1001078)", 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2014, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.552 | Q22 | What is Qinlock? | Qinlock, also known generically as Ripretinib, was approved by the FDA in 2020 to treat neoplasm and gastrointestinal stromal tumor. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%qinlock%" OR LOWER(tradeNames_string) LIKE "%qinlock%" OR LOWER(drugSynonyms_string) LIKE "%qinlock%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3036', 'tradeNames_string': 'Qinlock', 'drugName': 'Ripretinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Stem cell growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Gastrointestinal Stromal Tumor (MONDO_0011719), Neoplasm (EFO_0000616)', 'newLinkedTargets_string': 'PDGFRA (ENSG00000134853), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2020, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3037', 'tradeNames_string': 'Qinlock', 'drugName': 'Ripretinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Platelet-derived growth factor receptor alpha inhibitor', 'linkedDiseasesDrug_string': 'Gastrointestinal Stromal Tumor (MONDO_0011719), Neoplasm (EFO_0000616)', 'newLinkedTargets_string': 'PDGFRA (ENSG00000134853), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2020, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.473 | Q22 | What is Striverdi Respimat? | Striverdi Respimat, also known generically as Olodaterol, was approved by the FDA in 2014 to treat Airway obstruction. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%striverdi respimat%" OR LOWER(tradeNames_string) LIKE "%striverdi respimat%" OR LOWER(drugSynonyms_string) LIKE "%striverdi respimat%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5322', 'tradeNames_string': 'Striverdi respimat', 'drugName': 'Olodaterol Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Beta-2 adrenergic receptor agonist', 'linkedDiseasesDrug_string': 'Chronic Bronchitis (EFO_0006505), Chronic Obstructive Pulmonary Disease (EFO_0000341), Emphysema (EFO_0000464)', 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2014, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4859', 'tradeNames_string': 'Striverdi respimat', 'drugName': 'Olodaterol', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Beta-2 adrenergic receptor agonist', 'linkedDiseasesDrug_string': 'Chronic Bronchitis (EFO_0006505), Asthma (MONDO_0004979), Liver Disease (EFO_0001421), Chronic Obstructive Pulmonary Disease (EFO_0000341), Airway Obstruction (HP_0006536), Emphysema (EFO_0000464)', 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2014, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.95 | Q22 | What is Rexulti? | Rexulti, also known generically as Brexpiprazole, was approved by the FDA in 2015 to treat unipolar depression, psychosis, schizoaffective disorder, major depressive disorder, and schizophrenia. It is a small molecule therapy that acts as a(n) partial agonist and antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%rexulti%" OR LOWER(tradeNames_string) LIKE "%rexulti%" OR LOWER(drugSynonyms_string) LIKE "%rexulti%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6348', 'tradeNames_string': 'Rexulti', 'drugName': 'Brexpiprazole', 'drugMolecularType': 'Small molecule', 'drugActionType': 'partial agonist', 'drugMechanismOfAction': 'Serotonin 1a (5-HT1a) receptor partial agonist', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Post-Traumatic Stress Disorder (EFO_0001358), Alzheimer Disease (MONDO_0004975), Sleep Disorder (EFO_0008568), Unipolar Depression (EFO_0003761), Bipolar I Disorder (EFO_0009963), Borderline Personality Disorder (HP_0012076), Agitation (HP_0000713), Schizoaffective Disorder (EFO_0005411), Major Depressive Disorder (MONDO_0002009), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090), Alcohol Dependence (MONDO_0007079)', 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), DRD2 (ENSG00000149295), HTR1A (ENSG00000178394)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_6349', 'tradeNames_string': 'Rexulti', 'drugName': 'Brexpiprazole', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Serotonin 2a (5-HT2a) receptor antagonist', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Post-Traumatic Stress Disorder (EFO_0001358), Alzheimer Disease (MONDO_0004975), Sleep Disorder (EFO_0008568), Unipolar Depression (EFO_0003761), Bipolar I Disorder (EFO_0009963), Borderline Personality Disorder (HP_0012076), Agitation (HP_0000713), Schizoaffective Disorder (EFO_0005411), Major Depressive Disorder (MONDO_0002009), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090), Alcohol Dependence (MONDO_0007079)', 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), DRD2 (ENSG00000149295), HTR1A (ENSG00000178394)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_6350', 'tradeNames_string': 'Rexulti', 'drugName': 'Brexpiprazole', 'drugMolecularType': 'Small molecule', 'drugActionType': 'partial agonist', 'drugMechanismOfAction': 'Dopamine D2 receptor partial agonist', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Post-Traumatic Stress Disorder (EFO_0001358), Alzheimer Disease (MONDO_0004975), Sleep Disorder (EFO_0008568), Unipolar Depression (EFO_0003761), Bipolar I Disorder (EFO_0009963), Borderline Personality Disorder (HP_0012076), Agitation (HP_0000713), Schizoaffective Disorder (EFO_0005411), Major Depressive Disorder (MONDO_0002009), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090), Alcohol Dependence (MONDO_0007079)', 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), DRD2 (ENSG00000149295), HTR1A (ENSG00000178394)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.8 | Q22 | What is Differin? | Differin, also known generically as Adapalene, was approved by the FDA in 1996 to treat acne. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%differin%" OR LOWER(tradeNames_string) LIKE "%differin%" OR LOWER(drugSynonyms_string) LIKE "%differin%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1916', 'tradeNames_string': 'Adapalene, Differin', 'drugName': 'Adapalene', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Retinoic acid receptor agonist', 'linkedDiseasesDrug_string': 'Skin Disease (EFO_0000701), Acne (EFO_0003894)', 'newLinkedTargets_string': 'RARG (ENSG00000172819), RARB (ENSG00000077092), RARA (ENSG00000131759)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1996, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.92 | Q22 | What is Bosulif? | Bosulif, also known generically as Bosutinib, was approved by the FDA in 2010 to treat chronic myelogenous leukemia and neoplasm. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bosulif%" OR LOWER(tradeNames_string) LIKE "%bosulif%" OR LOWER(drugSynonyms_string) LIKE "%bosulif%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3955', 'tradeNames_string': 'Bosulif', 'drugName': 'Bosutinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Bcr/Abl fusion protein', 'linkedDiseasesDrug_string': 'Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131), Chronic Myelogenous Leukemia (EFO_0000339), Ovarian Cancer (MONDO_0008170), Breast Carcinoma (EFO_0000305), Breast Cancer (MONDO_0007254), Autosomal Dominant Polycystic Kidney Disease (EFO_1001496), Dementia (HP_0000726), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Pancreatic Carcinoma (EFO_0002618), Thymus Cancer (MONDO_0002586), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Cervical Cancer (MONDO_0002974), Thymoma (EFO_1000581), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Urinary Bladder Cancer (MONDO_0001187), Amyotrophic Lateral Sclerosis (MONDO_0004976), Non-Small Cell Lung Carcinoma (EFO_0003060), Glioblastoma Multiforme (EFO_0000519)', 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716), HCK (ENSG00000101336), SRC (ENSG00000197122), LYN (ENSG00000254087)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2010, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3956', 'tradeNames_string': 'Bosulif', 'drugName': 'Bosutinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase HCK inhibitor', 'linkedDiseasesDrug_string': 'Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131), Chronic Myelogenous Leukemia (EFO_0000339), Ovarian Cancer (MONDO_0008170), Breast Carcinoma (EFO_0000305), Breast Cancer (MONDO_0007254), Autosomal Dominant Polycystic Kidney Disease (EFO_1001496), Dementia (HP_0000726), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Pancreatic Carcinoma (EFO_0002618), Thymus Cancer (MONDO_0002586), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Cervical Cancer (MONDO_0002974), Thymoma (EFO_1000581), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Urinary Bladder Cancer (MONDO_0001187), Amyotrophic Lateral Sclerosis (MONDO_0004976), Non-Small Cell Lung Carcinoma (EFO_0003060), Glioblastoma Multiforme (EFO_0000519)', 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716), HCK (ENSG00000101336), SRC (ENSG00000197122), LYN (ENSG00000254087)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2010, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3957', 'tradeNames_string': 'Bosulif', 'drugName': 'Bosutinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase SRC inhibitor', 'linkedDiseasesDrug_string': 'Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131), Chronic Myelogenous Leukemia (EFO_0000339), Ovarian Cancer (MONDO_0008170), Breast Carcinoma (EFO_0000305), Breast Cancer (MONDO_0007254), Autosomal Dominant Polycystic Kidney Disease (EFO_1001496), Dementia (HP_0000726), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Pancreatic Carcinoma (EFO_0002618), Thymus Cancer (MONDO_0002586), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Cervical Cancer (MONDO_0002974), Thymoma (EFO_1000581), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Urinary Bladder Cancer (MONDO_0001187), Amyotrophic Lateral Sclerosis (MONDO_0004976), Non-Small Cell Lung Carcinoma (EFO_0003060), Glioblastoma Multiforme (EFO_0000519)', 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716), HCK (ENSG00000101336), SRC (ENSG00000197122), LYN (ENSG00000254087)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2010, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3958', 'tradeNames_string': 'Bosulif', 'drugName': 'Bosutinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase Lyn inhibitor', 'linkedDiseasesDrug_string': 'Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131), Chronic Myelogenous Leukemia (EFO_0000339), Ovarian Cancer (MONDO_0008170), Breast Carcinoma (EFO_0000305), Breast Cancer (MONDO_0007254), Autosomal Dominant Polycystic Kidney Disease (EFO_1001496), Dementia (HP_0000726), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Pancreatic Carcinoma (EFO_0002618), Thymus Cancer (MONDO_0002586), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Cervical Cancer (MONDO_0002974), Thymoma (EFO_1000581), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Urinary Bladder Cancer (MONDO_0001187), Amyotrophic Lateral Sclerosis (MONDO_0004976), Non-Small Cell Lung Carcinoma (EFO_0003060), Glioblastoma Multiforme (EFO_0000519)', 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716), HCK (ENSG00000101336), SRC (ENSG00000197122), LYN (ENSG00000254087)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2010, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3959', 'tradeNames_string': 'Bosulif', 'drugName': 'Bosutinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase ABL inhibitor', 'linkedDiseasesDrug_string': 'Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131), Chronic Myelogenous Leukemia (EFO_0000339), Ovarian Cancer (MONDO_0008170), Breast Carcinoma (EFO_0000305), Breast Cancer (MONDO_0007254), Autosomal Dominant Polycystic Kidney Disease (EFO_1001496), Dementia (HP_0000726), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Pancreatic Carcinoma (EFO_0002618), Thymus Cancer (MONDO_0002586), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Cervical Cancer (MONDO_0002974), Thymoma (EFO_1000581), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Urinary Bladder Cancer (MONDO_0001187), Amyotrophic Lateral Sclerosis (MONDO_0004976), Non-Small Cell Lung Carcinoma (EFO_0003060), Glioblastoma Multiforme (EFO_0000519)', 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716), HCK (ENSG00000101336), SRC (ENSG00000197122), LYN (ENSG00000254087)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2010, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.535 | Q22 | What is Flo-Pred? | Flo-Pred, also known generically as Prednisolone Acetate, was approved by the FDA in 1955 to treat Corneal scarring, Nasal congestion, inflammation, eye inflammation, allergic conjunctivitis, hemorrhoid, anemia, and multiple sclerosis. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%flo-pred%" OR LOWER(tradeNames_string) LIKE "%flo-pred%" OR LOWER(drugSynonyms_string) LIKE "%flo-pred%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5344', 'tradeNames_string': 'Econopred, Flo-pred, Meticortelone, Omnipred, Pred forte, Pred fte, Pred mild, Prednisolone acetate, Sterane, Ultracortenol', 'drugName': 'Prednisolone Acetate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucocorticoid receptor agonist', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Anterior Uveitis (EFO_1000811), Uveitis (EFO_1001231), Iritis (EFO_1000997), Retinal Vein Occlusion (EFO_1001157), Sciatica (HP_0011868), Cataract (MONDO_0005129), Multiple Sclerosis (MONDO_0005301), Hemorrhoid (EFO_0009552), Eye Inflammation (EFO_0005752), Corneal Scarring (HP_0000559), Inflammation (MP_0001845), Anemia (MONDO_0002280), Low Back Pain (HP_0003419), Nasal Congestion (HP_0001742), Eye Infection (EFO_1001888), Macular Retinal Edema (MONDO_0003005)', 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1955, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.386 | Q22 | What is Inveltys? | Inveltys, also known generically as Loteprednol Etabonate, was approved by the FDA in 1998 to treat inflammation, eye inflammation, allergic conjunctivitis, anterior uveitis, and dry eye syndrome. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%inveltys%" OR LOWER(tradeNames_string) LIKE "%inveltys%" OR LOWER(drugSynonyms_string) LIKE "%inveltys%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5556', 'tradeNames_string': 'Airex, Alrex, Eysuvis, Inveltys, Lotemax, Lotemax sm', 'drugName': 'Loteprednol Etabonate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucocorticoid receptor agonist', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Anterior Uveitis (EFO_1000811), Blepharitis (EFO_0009536), Cataract (MONDO_0005129), Ocular Pain (HP_0200026), Eye Inflammation (EFO_0005752), Inflammation (MP_0001845), Dry Eye Syndrome (EFO_1000906)', 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1998, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.528 | Q22 | What is Pomalyst? | Pomalyst, also known generically as Pomalidomide, was approved by the FDA in 2013 to treat immune system disease and multiple myeloma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pomalyst%" OR LOWER(tradeNames_string) LIKE "%pomalyst%" OR LOWER(drugSynonyms_string) LIKE "%pomalyst%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4886', 'tradeNames_string': 'Imnovid, Pomalyst', 'drugName': 'Pomalidomide', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'CRL4(CRBN) E3 ubiquitin ligase inhibitor', 'linkedDiseasesDrug_string': "Asymptomatic Myeloma (EFO_0003073), Multiple Myeloma (EFO_0001378), Non-Hodgkins Lymphoma (EFO_0005952), Primary Myelofibrosis (EFO_0002430), Medulloblastoma (EFO_0002939), Al Amyloidosis (MONDO_0019438), Graft Versus Host Disease (MONDO_0013730), Plasmacytoma (EFO_0006738), Burkitts Lymphoma (EFO_0000309), Hereditary Hemorrhagic Telangiectasia (MONDO_0019180), Plasma Cell Leukemia (EFO_0006475), Polycythemia Vera (EFO_0002429), Prostate Cancer (MONDO_0008315), Myelofibrosis (MONDO_0044903), Interstitial Lung Disease (EFO_0004244), Diffuse Large B-Cell Lymphoma (EFO_0000403), Immune System Disease (EFO_0000540), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Sickle Cell Anemia (MONDO_0011382), Soft Tissue Sarcoma (EFO_1001968), Waldenstrom Macroglobulinemia (EFO_0009441), Castleman Disease (MONDO_0015564), Systemic Scleroderma (EFO_0000717), Hodgkins Lymphoma (EFO_0000183), Neoplasm (EFO_0000616), Myeloproliferative Disorder (EFO_0004251), Kaposi'S Sarcoma (EFO_0000558), Primary Systemic Amyloidosis (MONDO_0017816), Pulmonary Fibrosis (EFO_0009448)", 'newLinkedTargets_string': 'CRBN (ENSG00000113851), DDB1 (ENSG00000167986), CUL4A (ENSG00000139842), RBX1 (ENSG00000100387)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2013, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.546 | Q22 | What is Rebetol? | Rebetol, also known generically as Ribavirin, was approved by the FDA in 1985 to treat viral disease, cirrhosis of liver, chronic hepatitis C virus infection, and fibrosis. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%rebetol%" OR LOWER(tradeNames_string) LIKE "%rebetol%" OR LOWER(drugSynonyms_string) LIKE "%rebetol%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3809', 'tradeNames_string': 'Copegus, Rebetol, Ribapak, Ribasphere, Ribavarin, Ribavirin, Ribofluranosyl Carboxamide, Tribavirin, Viramid, Virazid, Virazole', 'drugName': 'Ribavirin', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': "Inosine-5'-monophosphate dehydrogenase 1 inhibitor", 'linkedDiseasesDrug_string': 'Infection (EFO_0000544), Fibrosis (EFO_0006890), Covid-19 (MONDO_0100096), Lassa Fever (EFO_0007338), Hepatitis C Virus Infection (EFO_0003047), Breast Cancer (MONDO_0007254), Hepatitis B Virus Infection (EFO_0004197), Chronic Hepatitis B Virus Infection (EFO_0004239), Hepatitis D Virus Infection (EFO_0007304), Acute Myeloid Leukemia (EFO_0000222), Thrombocytopenia (HP_0001873), Viral Disease (EFO_0000763), Respiratory Syncytial Virus Infection (EFO_1001413), Chronic Hepatitis C Virus Infection (EFO_0004220), Influenza (EFO_0007328), Depressive Disorder (MONDO_0002050), Hemorrhagic Fever With Renal Syndrome (EFO_0007299), Hiv Infection (EFO_0000764), Neoplasm (EFO_0000616), Hepatitis (HP_0012115), Japanese Encephalitis (EFO_0007332), Type 1 Diabetes Mellitus (MONDO_0005147), Severe Acute Respiratory Syndrome (EFO_0000694), Cirrhosis Of Liver (EFO_0001422)', 'newLinkedTargets_string': 'IMPDH1 (ENSG00000106348)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1985, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3810', 'tradeNames_string': 'Copegus, Rebetol, Ribapak, Ribasphere, Ribavarin, Ribavirin, Ribofluranosyl Carboxamide, Tribavirin, Viramid, Virazid, Virazole', 'drugName': 'Ribavirin', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitor', 'linkedDiseasesDrug_string': 'Infection (EFO_0000544), Fibrosis (EFO_0006890), Covid-19 (MONDO_0100096), Lassa Fever (EFO_0007338), Hepatitis C Virus Infection (EFO_0003047), Breast Cancer (MONDO_0007254), Hepatitis B Virus Infection (EFO_0004197), Chronic Hepatitis B Virus Infection (EFO_0004239), Hepatitis D Virus Infection (EFO_0007304), Acute Myeloid Leukemia (EFO_0000222), Thrombocytopenia (HP_0001873), Viral Disease (EFO_0000763), Respiratory Syncytial Virus Infection (EFO_1001413), Chronic Hepatitis C Virus Infection (EFO_0004220), Influenza (EFO_0007328), Depressive Disorder (MONDO_0002050), Hemorrhagic Fever With Renal Syndrome (EFO_0007299), Hiv Infection (EFO_0000764), Neoplasm (EFO_0000616), Hepatitis (HP_0012115), Japanese Encephalitis (EFO_0007332), Type 1 Diabetes Mellitus (MONDO_0005147), Severe Acute Respiratory Syndrome (EFO_0000694), Cirrhosis Of Liver (EFO_0001422)', 'newLinkedTargets_string': 'IMPDH1 (ENSG00000106348)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1985, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.369 | Q22 | What is Thyquidity? | Thyquidity, also known generically as Levothyroxine Sodium, was approved by the FDA in 2000 to treat thyroid carcinoma, hypothyroidism, differentiated thyroid carcinoma, thyroid cancer, and congenital hypothyroidism. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%thyquidity%" OR LOWER(tradeNames_string) LIKE "%thyquidity%" OR LOWER(drugSynonyms_string) LIKE "%thyquidity%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5964', 'tradeNames_string': 'Eltroxin, Ermeza, Euthyrox, Evotrox, L-thyroxine henning, Levo-t, Levolet, Levothroid, Levothyroid, Levothyroxine sodium, Levoxine, Levoxyl, Novothyrox, Soloxine, Synthroid, Thyquidity, Thyro-tabs, Thyrol L, Thyroxine, Tirosint, Tirosint-sol, Unithroid', 'drugName': 'Levothyroxine Sodium', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Thyroid hormone receptor agonist', 'linkedDiseasesDrug_string': 'Congenital Hypothyroidism (MONDO_0018612), Pain (EFO_0003843), Thyroid Carcinoma (EFO_0002892), Thyroid Cancer (MONDO_0002108), Bipolar Disorder (MONDO_0004985), Hypothyroidism (EFO_0004705), Differentiated Thyroid Carcinoma (EFO_1002017)', 'newLinkedTargets_string': 'THRA (ENSG00000126351), THRB (ENSG00000151090)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2000, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.645 | Q22 | What is Fotivda? | Fotivda, also known generically as Tivozanib, was approved by the FDA in 2021 to treat neoplasm. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fotivda%" OR LOWER(tradeNames_string) LIKE "%fotivda%" OR LOWER(drugSynonyms_string) LIKE "%fotivda%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2104', 'tradeNames_string': 'Fotivda', 'drugName': 'Tivozanib Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Vascular endothelial growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Renal Cell Carcinoma (EFO_0000681), Liver Disease (EFO_0001421), Breast Cancer (MONDO_0007254)', 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2105', 'tradeNames_string': 'Fotivda', 'drugName': 'Tivozanib Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Stem cell growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Renal Cell Carcinoma (EFO_0000681), Liver Disease (EFO_0001421), Breast Cancer (MONDO_0007254)', 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2106', 'tradeNames_string': 'Fotivda', 'drugName': 'Tivozanib Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Platelet-derived growth factor receptor beta inhibitor', 'linkedDiseasesDrug_string': 'Renal Cell Carcinoma (EFO_0000681), Liver Disease (EFO_0001421), Breast Cancer (MONDO_0007254)', 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_874', 'tradeNames_string': 'Fotivda', 'drugName': 'Tivozanib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Vascular endothelial growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Fallopian Tube Cancer (MONDO_0002158), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Liver Disease (EFO_0001421), Non-Small Cell Lung Carcinoma (EFO_0003060), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Glioblastoma Multiforme (EFO_0000519), Colorectal Carcinoma (EFO_1001951), Cholangiocarcinoma (EFO_0005221), Ovarian Cancer (MONDO_0008170)', 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_875', 'tradeNames_string': 'Fotivda', 'drugName': 'Tivozanib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Stem cell growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Fallopian Tube Cancer (MONDO_0002158), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Liver Disease (EFO_0001421), Non-Small Cell Lung Carcinoma (EFO_0003060), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Glioblastoma Multiforme (EFO_0000519), Colorectal Carcinoma (EFO_1001951), Cholangiocarcinoma (EFO_0005221), Ovarian Cancer (MONDO_0008170)', 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_876', 'tradeNames_string': 'Fotivda', 'drugName': 'Tivozanib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Platelet-derived growth factor receptor beta inhibitor', 'linkedDiseasesDrug_string': 'Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Fallopian Tube Cancer (MONDO_0002158), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Liver Disease (EFO_0001421), Non-Small Cell Lung Carcinoma (EFO_0003060), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Glioblastoma Multiforme (EFO_0000519), Colorectal Carcinoma (EFO_1001951), Cholangiocarcinoma (EFO_0005221), Ovarian Cancer (MONDO_0008170)', 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.143 | Q22 | What is Cleviprex? | Cleviprex, also known generically as Clevidipine, was approved by the FDA in 2008 to treat cardiovascular disease. It is a small molecule therapy that acts as a(n) blocker. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cleviprex%" OR LOWER(tradeNames_string) LIKE "%cleviprex%" OR LOWER(drugSynonyms_string) LIKE "%cleviprex%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_250', 'tradeNames_string': 'Cleviprex', 'drugName': 'Clevidipine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Voltage-gated L-type calcium channel blocker', 'linkedDiseasesDrug_string': 'Malignant Hypertension (EFO_1001031), Stroke (EFO_0000712), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Vascular Disease (EFO_0004264), Scoliosis (EFO_0004273)', 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2008, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.29 | Q22 | What is Osmolex Er? | Osmolex Er, also known generically as Amantadine Hydrochloride, was approved by the FDA in 1968 to treat Parkinsonism, infection, influenza, cerebral atherosclerosis, secondary Parkinson disease, postencephalitic Parkinson disease, and Parkinson disease. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%osmolex er%" OR LOWER(tradeNames_string) LIKE "%osmolex er%" OR LOWER(drugSynonyms_string) LIKE "%osmolex er%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_768', 'tradeNames_string': 'Amantadine hydrochloride, Gocovri, Lysovir, Mantadine, Osmolex er, Symadine, Symmetrel', 'drugName': 'Amantadine Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Glutamate [NMDA] receptor antagonist', 'linkedDiseasesDrug_string': 'Parkinsonism (HP_0001300), Secondary Parkinson Disease (EFO_1001175), Infection (EFO_0000544), Mood Disorder (EFO_0004247), Multiple Sclerosis (MONDO_0005301), Covid-19 (MONDO_0100096), Postencephalitic Parkinson Disease (EFO_1001402), Cerebral Atherosclerosis (EFO_1000860), Parkinson Disease (MONDO_0005180), Schizoaffective Disorder (EFO_0005411), Brain Injury (MONDO_0043510), Influenza (EFO_0007328), Schizophrenia (MONDO_0005090), Hepatitis C Virus Infection (EFO_0003047)', 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1968, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_769', 'tradeNames_string': 'Amantadine hydrochloride, Gocovri, Lysovir, Mantadine, Osmolex er, Symadine, Symmetrel', 'drugName': 'Amantadine Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Matrix protein 2 inhibitor', 'linkedDiseasesDrug_string': 'Parkinsonism (HP_0001300), Secondary Parkinson Disease (EFO_1001175), Infection (EFO_0000544), Mood Disorder (EFO_0004247), Multiple Sclerosis (MONDO_0005301), Covid-19 (MONDO_0100096), Postencephalitic Parkinson Disease (EFO_1001402), Cerebral Atherosclerosis (EFO_1000860), Parkinson Disease (MONDO_0005180), Schizoaffective Disorder (EFO_0005411), Brain Injury (MONDO_0043510), Influenza (EFO_0007328), Schizophrenia (MONDO_0005090), Hepatitis C Virus Infection (EFO_0003047)', 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1968, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.44 | Q22 | What is Kynmobi? | Kynmobi, also known generically as Apomorphine Hydrochloride, was approved by the FDA in 2004 to treat Parkinson disease. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%kynmobi%" OR LOWER(tradeNames_string) LIKE "%kynmobi%" OR LOWER(drugSynonyms_string) LIKE "%kynmobi%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3300', 'tradeNames_string': 'Apo-go, Apo-go pen, Apo-go pfs, Apokyn, Apomorph hcl, Britaject, Bromophin, Dacepton, Diagesil, Diamorph hcl, Diamorph roche, Diamorph,cocaine,chlorpromazine, Diaphine, Euphorin, Kynmobi, Uprima', 'drugName': 'Apomorphine Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'D2-like dopamine receptor agonist', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616), Osteoporosis (EFO_0003882), Parkinson Disease (MONDO_0005180)', 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2004, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.43 | Q22 | What is Eliquis? | Eliquis, also known generically as Apixaban, was approved by the FDA in 2012 to treat Recurrent thrombophlebitis, Venous thrombosis, atrial fibrillation, stroke, pulmonary embolism, deep vein thrombosis, and thrombotic disease. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%eliquis%" OR LOWER(tradeNames_string) LIKE "%eliquis%" OR LOWER(drugSynonyms_string) LIKE "%eliquis%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4326', 'tradeNames_string': 'Eliquis', 'drugName': 'Apixaban', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Coagulation factor X inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Hemorrhage (MP_0001914), Covid-19 (MONDO_0100096), Venous Thrombosis (HP_0004936), Pulmonary Embolism (EFO_0003827), Atrial Fibrillation (EFO_0000275), Nephrotic Syndrome (EFO_0004255), Recurrent Thrombophlebitis (HP_0004419), Ischemic Stroke (HP_0002140), Patent Foramen Ovale (HP_0001655), Acute Lymphoblastic Leukemia (EFO_0000220), Thrombotic Disease (MONDO_0000831), Acute Coronary Syndrome (EFO_0005672), Thromboembolism (HP_0001907), Renal Insufficiency (HP_0000083), Takotsubo Cardiomyopathy (EFO_1002000), Hematoma (EFO_0010680), Atrial Flutter (EFO_0003911), Aortic Stenosis (EFO_0000266), Stroke (EFO_0000712), Sickle Cell Anemia (MONDO_0011382), Venous Thromboembolism (EFO_0004286), Chronic Kidney Disease (EFO_0003884), Heart Failure (EFO_0003144), Deep Vein Thrombosis (EFO_0003907), Ischemia (EFO_0000556), Blood Coagulation Disease (EFO_0009314), Cirrhosis Of Liver (EFO_0001422)', 'newLinkedTargets_string': 'F10 (ENSG00000126218)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.74 | Q22 | What is Qvar 40? | Qvar 40, also known generically as Beclomethasone Dipropionate, was approved by the FDA in 1976 to treat Nasal congestion, Airway obstruction, seasonal allergic rhinitis, allergic rhinitis, Rhinitis, Allergic, Perennial, and asthma. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%qvar 40%" OR LOWER(tradeNames_string) LIKE "%qvar 40%" OR LOWER(drugSynonyms_string) LIKE "%qvar 40%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5013', 'tradeNames_string': 'Aerobec 100, Aerobec 50, Aerobec fte 250, Asmabec clickhaler, Asmabec spacehaler, Beclazone 100, Beclazone 100 e-breathe, Beclazone 200, Beclazone 250, Beclazone 250 e-breathe, Beclazone 50, Beclazone 50 e-breathe, Becloaqua 50, Becloforte, Becloforte e-breathe, Becloforte integra, Becloforte-vm, Beclomet diprop, Beclomet hayfever, Beclomist, Beclotaide, Beclovent, Becodisks, Beconase, Beconase aq, Becotide, Becotide 100, Becotide 100 e-breathe, Becotide 200, Becotide 50, Becotide 50 e-breathe, Clenil modulite, Clipper, Filair 100, Filair 50, Filair fte, Fostair, Fostair nexthaler, Nasobec aq, Nasobec hayfever, Propaderm, Propaderm fte, Propaderm-a, Propaderm-c, Pulvinal beclomet, Qnasl, Qvar 100, Qvar 100 e-breathe, Qvar 40, Qvar 50, Qvar 50 e-breathe, Qvar 80, Qvar redihaler, Rino clenil, Vancenase, Vancenase aq, Vancenase pockethaler, Vanceril, Vanceril double strength, Ventide, Vivabec, Zonivent aquanasal', 'drugName': 'Beclomethasone Dipropionate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucocorticoid receptor agonist', 'linkedDiseasesDrug_string': 'Infection (EFO_0000544), Graft Versus Host Disease (MONDO_0013730), Covid-19 (MONDO_0100096), Allergic Rhinitis (EFO_0005854), Idiopathic Pulmonary Fibrosis (EFO_0000768), Seasonal Allergic Rhinitis (EFO_0003956), Acute Graft Vs. Host Disease (EFO_0004599), Nasal Cavity Polyp (EFO_1000391), Sinusitis (EFO_0007486), Asthma (MONDO_0004979), Small Cell Lung Carcinoma (EFO_0000702), Bronchiectasis (HP_0002110), Rhinitis, Allergic, Perennial (EFO_1001417), Chronic Obstructive Pulmonary Disease (EFO_0000341), Airway Obstruction (HP_0006536), Nasal Congestion (HP_0001742), Croup (EFO_0007227), Newborn Respiratory Distress Syndrome (EFO_1000644), Enteritis (MONDO_0043579), Folliculitis (EFO_1000702), Eosinophilic Esophagitis (EFO_0004232), Bronchopulmonary Dysplasia (MONDO_0019091)', 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1976, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.170 | Q22 | What is Ryanodex? | Ryanodex, also known generically as Dantrolene Sodium, was approved by the FDA in 1974 to treat Spasticity, Fever, stroke, cerebral palsy, Spinal cord injury, and multiple sclerosis. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ryanodex%" OR LOWER(tradeNames_string) LIKE "%ryanodex%" OR LOWER(drugSynonyms_string) LIKE "%ryanodex%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4504', 'tradeNames_string': 'Dantrium, Dantrolene sodium, Revonto, Ryanodex', 'drugName': 'Dantrolene Sodium', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Ryanodine receptor 3 antagonist', 'linkedDiseasesDrug_string': 'Drug Toxicity (EFO_0020003), Cerebral Palsy (EFO_1000632), Heat Stroke (EFO_1001340), Multiple Sclerosis (MONDO_0005301), Stroke (EFO_0000712), Fever (HP_0001945), Wolfram Syndrome (MONDO_0018105), Spasticity (HP_0001257), Spinal Cord Injury (EFO_1001919)', 'newLinkedTargets_string': 'RYR3 (ENSG00000198838), RYR1 (ENSG00000196218)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1974, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4505', 'tradeNames_string': 'Dantrium, Dantrolene sodium, Revonto, Ryanodex', 'drugName': 'Dantrolene Sodium', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Ryanodine receptor 1 antagonist', 'linkedDiseasesDrug_string': 'Drug Toxicity (EFO_0020003), Cerebral Palsy (EFO_1000632), Heat Stroke (EFO_1001340), Multiple Sclerosis (MONDO_0005301), Stroke (EFO_0000712), Fever (HP_0001945), Wolfram Syndrome (MONDO_0018105), Spasticity (HP_0001257), Spinal Cord Injury (EFO_1001919)', 'newLinkedTargets_string': 'RYR3 (ENSG00000198838), RYR1 (ENSG00000196218)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1974, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.214 | Q22 | What is Cerdelga? | Cerdelga, also known generically as Eliglustat Tartrate, was approved by the FDA in 2014 to treat Gaucher disease. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cerdelga%" OR LOWER(tradeNames_string) LIKE "%cerdelga%" OR LOWER(drugSynonyms_string) LIKE "%cerdelga%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4249', 'tradeNames_string': 'Cerdelga', 'drugName': 'Eliglustat', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Ceramide glucosyltransferase inhibitor', 'linkedDiseasesDrug_string': 'Gaucher Disease (MONDO_0018150), Gaucher Disease Type 3 (Orphanet_77261), Gaucher Disease Type 1 (Orphanet_77259), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881)', 'newLinkedTargets_string': 'UGCG (ENSG00000148154)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2014, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5337', 'tradeNames_string': 'Cerdelga', 'drugName': 'Eliglustat Tartrate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Ceramide glucosyltransferase inhibitor', 'linkedDiseasesDrug_string': 'Gaucher Disease (MONDO_0018150)', 'newLinkedTargets_string': 'UGCG (ENSG00000148154)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2014, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.617 | Q22 | What is Fabior? | Fabior, also known generically as Tazarotene, was approved by the FDA in 1997 to treat psoriasis, acne, psoriasis vulgaris, lentigo, and Genetic hypopigmentation of the skin. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fabior%" OR LOWER(tradeNames_string) LIKE "%fabior%" OR LOWER(drugSynonyms_string) LIKE "%fabior%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5124', 'tradeNames_string': 'Arazlo, Avage, Fabior, Tazorac, Zorac', 'drugName': 'Tazarotene', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Retinoic acid receptor agonist', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Genetic Hypopigmentation Of The Skin (Orphanet_183469), Skin Carcinoma (EFO_0009259), Skin Disease (EFO_0000701), Acne (EFO_0003894), Cutaneous T-Cell Lymphoma (EFO_0002913), Lentigo (MONDO_0021582), Psoriasis Vulgaris (EFO_1001494)', 'newLinkedTargets_string': 'RARG (ENSG00000172819), RARB (ENSG00000077092), RARA (ENSG00000131759)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1997, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.67 | Q22 | What is Fleqsuvy? | Fleqsuvy, also known generically as Baclofen, was approved by the FDA in 1977 to treat Spasticity, Rigidity, spinal cord disease, cerebral palsy, Spinal cord injury, multiple sclerosis, and brain injury. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fleqsuvy%" OR LOWER(tradeNames_string) LIKE "%fleqsuvy%" OR LOWER(drugSynonyms_string) LIKE "%fleqsuvy%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3627', 'tradeNames_string': 'Baclofen, Baclospas-10, Fleqsuvy, Gablofen, Kemstro, Lioresal, Lioresal intrath, Lyflex, Lyvispah, Ozobax', 'drugName': 'Baclofen', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'GABA-B receptor agonist', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Cerebral Palsy (EFO_1000632), Spinal Cord Disease (EFO_0009488), Multiple Sclerosis (MONDO_0005301), Pain (EFO_0003843), Obesity (EFO_0001073), Spasticity (HP_0001257), Cannabis Dependence (EFO_0007191), Reproductive System Disease (EFO_0000512), Spinal Cord Injury (EFO_1001919), Charcot-Marie-Tooth Disease (MONDO_0015626), Hepatocellular Carcinoma (EFO_0000182), Nicotine Dependence (EFO_0003768), Fragile X Syndrome (MONDO_0010383), Cocaine Dependence (EFO_0002610), Alcohol Withdrawal (EFO_0004777), Drug Dependence (EFO_0003890), Rigidity (HP_0002063), Brain Injury (MONDO_0043510), Ataxia Telangiectasia (MONDO_0008840), Gastroesophageal Reflux Disease (EFO_0003948), Alcohol Dependence (MONDO_0007079), Alcoholic Liver Cirrhosis (EFO_1000802)', 'newLinkedTargets_string': 'GABBR1 (ENSG00000204681), GABBR2 (ENSG00000136928)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1977, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.12 | Q22 | What is Proair Hfa? | Proair Hfa, also known generically as Albuterol, was approved by the FDA in 1981 to treat Airway obstruction, Bronchospasm, chronic obstructive pulmonary disease, and asthma. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%proair hfa%" OR LOWER(tradeNames_string) LIKE "%proair hfa%" OR LOWER(drugSynonyms_string) LIKE "%proair hfa%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1434', 'tradeNames_string': 'Aerolin, Aerolin 400, Aerolin auto, Airomir, Airsalb, Albuterol, Asmasal clickhaler, Asmasal spacehaler, Asmaven, Asmavent, Cobutolin, Combivent, Combivent udvs, Ipramol steri-neb, Kentamol, Libetist, Maxivent, Proair Hfa, Proventil, Proventil Hfa, Rimasal, Salamol e-breathe, Salapin, Salbulin novolizer, Salbuvent, Salipraneb, Steri-neb salamol, Ventmax sr, Ventodisks, Ventolin, Ventolin Hfa, Ventolin cr, Ventolin e-breathe, Volmax', 'drugName': 'Albuterol', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Beta-2 adrenergic receptor agonist', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Status Asthmaticus (EFO_0008590), Pulmonary Hypertension (MONDO_0005149), Cough (HP_0012735), Pulmonary Arterial Hypertension (EFO_0001361), Idiopathic Pulmonary Fibrosis (EFO_0000768), Lung Disease (EFO_0003818), Spinal Cord Injury (EFO_1001919), Bronchiolitis (HP_0011950), Idiopathic Pulmonary Arterial Hypertension (MONDO_0017147), Bronchospasm (HP_0025428), Congestive Heart Failure (EFO_0000373), Lymphangioleiomyomatosis (MONDO_0011705), Seasonal Allergic Rhinitis (EFO_0003956), Cardiovascular Disease (EFO_0000319), Adult Acute Respiratory Distress Syndrome (MONDO_0100130), Pulmonary Edema (EFO_1001134), Organophosphate Poisoning (EFO_0010581), Familial Dysautonomia (Orphanet_1764), Asthma (MONDO_0004979), Memory Impairment (EFO_0001072), Tachypnea (EFO_0009840), Chronic Obstructive Pulmonary Disease (EFO_0000341), Primary Ciliary Dyskinesia (MONDO_0016575), Airway Obstruction (HP_0006536), Glycogen Storage Disease Due To Acid Maltase Deficiency (Orphanet_365), Allergic Disease (MONDO_0005271), Congenital Myasthenic Syndromes (Orphanet_590), Respiratory Failure (EFO_0009686), Major Depressive Disorder (MONDO_0002009)', 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1981, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_6278', 'tradeNames_string': 'Accuneb, Albuterol sulfate, Proair, Proair digihaler, Proair hfa, Proair respiclick, Proventil, Proventil-hfa, Ventolin, Ventolin hfa, Ventolin rotacaps, Volmax, Vospire er', 'drugName': 'Albuterol Sulfate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Beta-2 adrenergic receptor agonist', 'linkedDiseasesDrug_string': 'Status Asthmaticus (EFO_0008590), Bronchospasm (HP_0025428), Asthma (MONDO_0004979), Chronic Obstructive Pulmonary Disease (EFO_0000341), Cardiovascular Disease (EFO_0000319), Adult Acute Respiratory Distress Syndrome (MONDO_0100130), Lung Disease (EFO_0003818)', 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1982, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.666 | Q22 | What is Tyvaso? | Tyvaso, also known generically as Treprostinil, was approved by the FDA in 2002 to treat Recurrent thrombophlebitis, pulmonary arterial hypertension, and pulmonary hypertension. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tyvaso%" OR LOWER(tradeNames_string) LIKE "%tyvaso%" OR LOWER(drugSynonyms_string) LIKE "%tyvaso%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1758', 'tradeNames_string': 'Remodulin, Tyvaso, Tyvaso dpi', 'drugName': 'Treprostinil', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Prostanoid IP receptor agonist', 'linkedDiseasesDrug_string': 'Recurrent Thrombophlebitis (HP_0004419), Pulmonary Hypertension (MONDO_0005149), Primary Pulmonary Hypertension (MONDO_0001999), Ischemia Reperfusion Injury (EFO_0002687), Raynaud Disease (EFO_1001145), Chronic Obstructive Pulmonary Disease (EFO_0000341), Adult Acute Respiratory Distress Syndrome (MONDO_0100130), Persistent Fetal Circulation Syndrome (EFO_1001103), Peripheral Vascular Disease (EFO_0003875), Pulmonary Arterial Hypertension (EFO_0001361), Diabetic Foot (EFO_1001459), Type 1 Diabetes Mellitus (MONDO_0005147), Idiopathic Pulmonary Fibrosis (EFO_0000768), Systemic Scleroderma (EFO_0000717), Ischemia (EFO_0000556), Congenital Heart Disease (EFO_0005207)', 'newLinkedTargets_string': 'PTGIR (ENSG00000160013)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2002, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.574 | Q22 | What is Xpovio? | Xpovio, also known generically as Selinexor, was approved by the FDA in 2019 to treat cancer, diffuse large B-cell lymphoma, neoplasm, and multiple myeloma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%xpovio%" OR LOWER(tradeNames_string) LIKE "%xpovio%" OR LOWER(drugSynonyms_string) LIKE "%xpovio%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_58', 'tradeNames_string': 'Xpovio', 'drugName': 'Selinexor', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Exportin-1 inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Al Amyloidosis (MONDO_0019438), Covid-19 (MONDO_0100096), Urothelial Carcinoma (EFO_0008528), Metastatic Melanoma (EFO_0002617), Squamous Cell Lung Carcinoma (EFO_0000708), Myelodysplastic Syndrome (EFO_0000198), Endometrial Cancer (MONDO_0011962), Chronic Myelogenous Leukemia (EFO_0000339), Lymphoid Neoplasm (EFO_0001642), Breast Carcinoma (EFO_0000305), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Fallopian Tube Carcinoma (EFO_1000251), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Colorectal Neoplasm (EFO_0004142), Myelofibrosis (MONDO_0044903), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Diabetic Foot (EFO_1001459), Acute Leukemia Of Ambiguous Lineage (MONDO_0019460), Diffuse Large B-Cell Lymphoma (EFO_0000403), Dedifferentiated Liposarcoma (EFO_0003085), Small Cell Lung Carcinoma (EFO_0000702), Neoplasm Of Mature B-Cells (EFO_0000096), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Cutaneous Melanoma (EFO_0000389), Thymoma (EFO_1000581), Rectum Cancer (EFO_1000657), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Alveolar Soft Part Sarcoma (EFO_0007143), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211)', 'newLinkedTargets_string': 'XPO1 (ENSG00000082898)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2019, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.181 | Q22 | What is Noctiva? | Noctiva, also known generically as Desmopressin Acetate, was approved by the FDA in 1978 to treat Central diabetes insipidus, Nasal congestion, hemorrhage, head injury, diabetes insipidus, enuresis, and von Willebrand disease (hereditary or acquired). It is a protein therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%noctiva%" OR LOWER(tradeNames_string) LIKE "%noctiva%" OR LOWER(drugSynonyms_string) LIKE "%noctiva%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2993', 'tradeNames_string': 'Concentraid, Ddavp, Ddavp (needs no refrigeration), Desmomelt, Desmopressin acetate, Desmopressin acetate (needs no refrigeration), Desmopressin acetate preservative free, Desmospray, Desmotabs, Minirin, Nocdurna, Noctiva, Nocutil, Noqdirna, Octim, Octostim, Presinex, Stimate, Stimate (needs no refrigeration)', 'drugName': 'Desmopressin Acetate', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Vasopressin receptor agonist', 'linkedDiseasesDrug_string': 'Intracerebral Hemorrhage (EFO_0005669), Enuresis (MONDO_0024290), Central Diabetes Insipidus (HP_0000863), Hemorrhage (MP_0001914), Hypertension (EFO_0000537), Ecchymosis (HP_0031364), Nasal Congestion (HP_0001742), Diabetes Insipidus (MONDO_0004782), Von Willebrand Disease (Hereditary Or Acquired) (MONDO_0024574), Head Injury (EFO_0009505)', 'newLinkedTargets_string': 'AVPR2 (ENSG00000126895), AVPR1A (ENSG00000166148), AVPR1B (ENSG00000198049)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1978, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.540 | Q22 | What is Aspruzyo Sprinkle? | Aspruzyo Sprinkle, also known generically as Ranolazine, was approved by the FDA in 2006 to treat cardiovascular disease and angina pectoris. It is a small molecule therapy that acts as a(n) blocker. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%aspruzyo sprinkle%" OR LOWER(tradeNames_string) LIKE "%aspruzyo sprinkle%" OR LOWER(drugSynonyms_string) LIKE "%aspruzyo sprinkle%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6340', 'tradeNames_string': 'Aspruzyo sprinkle, Ranexa, Ranolazine', 'drugName': 'Ranolazine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Sodium channel protein type IV alpha subunit blocker', 'linkedDiseasesDrug_string': "Prolonged Qt Interval (HP_0001657), Diastolic Heart Failure (EFO_1000899), Atrial Fibrillation (EFO_0000275), Crohn'S Disease (EFO_0000384), Angina Pectoris (EFO_0003913), Amyotrophic Lateral Sclerosis (MONDO_0004976), Paramyotonia Congenita Of Von Eulenburg (MONDO_0008195), Dilated Cardiomyopathy (EFO_0000407), Coronary Artery Disease (EFO_0001645), Cardiovascular Disease (EFO_0000319), Pulmonary Arterial Hypertension (EFO_0001361), Kidney Disease (EFO_0003086), Irritable Bowel Syndrome (EFO_0000555), Vascular Disease (EFO_0004264), Acute Coronary Syndrome (EFO_0005672), Type 2 Diabetes Mellitus (MONDO_0005148), Myocardial Ischemia (EFO_1001375)", 'newLinkedTargets_string': 'SCN4A (ENSG00000007314), SCN5A (ENSG00000183873)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2006, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_6341', 'tradeNames_string': 'Aspruzyo sprinkle, Ranexa, Ranolazine', 'drugName': 'Ranolazine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Sodium channel protein type V alpha subunit blocker', 'linkedDiseasesDrug_string': "Prolonged Qt Interval (HP_0001657), Diastolic Heart Failure (EFO_1000899), Atrial Fibrillation (EFO_0000275), Crohn'S Disease (EFO_0000384), Angina Pectoris (EFO_0003913), Amyotrophic Lateral Sclerosis (MONDO_0004976), Paramyotonia Congenita Of Von Eulenburg (MONDO_0008195), Dilated Cardiomyopathy (EFO_0000407), Coronary Artery Disease (EFO_0001645), Cardiovascular Disease (EFO_0000319), Pulmonary Arterial Hypertension (EFO_0001361), Kidney Disease (EFO_0003086), Irritable Bowel Syndrome (EFO_0000555), Vascular Disease (EFO_0004264), Acute Coronary Syndrome (EFO_0005672), Type 2 Diabetes Mellitus (MONDO_0005148), Myocardial Ischemia (EFO_1001375)", 'newLinkedTargets_string': 'SCN4A (ENSG00000007314), SCN5A (ENSG00000183873)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2006, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.363 | Q22 | What is Mirena? | Mirena, also known generically as Levonorgestrel, was approved by the FDA in 1982 to treat Menorrhagia. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mirena%" OR LOWER(tradeNames_string) LIKE "%mirena%" OR LOWER(drugSynonyms_string) LIKE "%mirena%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2857', 'tradeNames_string': 'Athentia next, Emerres, Emerres una, Ezinelle, Fallback solo, Her style, Isteranda, Jadelle, Jaydess, Kyleena, Levonelle, Levonelle one step, Levonelle-2, Levonorgestrel, Levosert, Liletta, Microval, Mirena, Norgeston, Norplant, Norplant Ii, Norplant System, Opcicon one-step, Ovrette, Plan B, Plan b one-step, Postinor-2, Skyla, Upostelle', 'drugName': 'Levonorgestrel', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Progesterone receptor agonist', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Adenomyosis (EFO_1001757), Menorrhagia (HP_0000132), Osteopenia (HP_0000938), Hiv Infection (EFO_0000764), Chronic Lymphocytic Leukemia (EFO_0000095), Chronic Hepatitis B Virus Infection (EFO_0004239), Hemorrhage (MP_0001914), Migraine Disorder (MONDO_0005277), Pain (EFO_0003843), Non-Alcoholic Steatohepatitis (EFO_1001249), Dysmenorrhea (HP_0100607), Hiv-1 Infection (EFO_0000180), Endometriosis (EFO_0001065), Chronic Hepatitis C Virus Infection (EFO_0004220), Type 2 Diabetes Mellitus (MONDO_0005148), Anorexia Nervosa (MONDO_0005351)', 'newLinkedTargets_string': 'PGR (ENSG00000082175)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1982, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.655 | Q22 | What is Soaanz? | Soaanz, also known generically as Torsemide, was approved by the FDA in 1993 to treat cardiovascular disease, congestive heart failure, hypertension, myocardial infarction, stroke, and heart failure. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%soaanz%" OR LOWER(tradeNames_string) LIKE "%soaanz%" OR LOWER(drugSynonyms_string) LIKE "%soaanz%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4709', 'tradeNames_string': 'Demadex, Soaanz, Torem 10, Torem 2.5, Torem 5, Torsemide', 'drugName': 'Torsemide', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Sodium-(potassium)-chloride cotransporter 2 inhibitor', 'linkedDiseasesDrug_string': 'Congestive Heart Failure (EFO_0000373), Preeclampsia (EFO_0000668), Stroke (EFO_0000712), Heart Failure (EFO_0003144), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Myocardial Infarction (EFO_0000612), Type 2 Diabetes Mellitus (MONDO_0005148)', 'newLinkedTargets_string': 'SLC12A1 (ENSG00000074803)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1993, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.295 | Q22 | What is Zoladex? | Zoladex, also known generically as Goserelin Acetate, was approved by the FDA in 1989 to treat breast carcinoma, carcinoma, and breast cancer. It is a protein therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%zoladex%" OR LOWER(tradeNames_string) LIKE "%zoladex%" OR LOWER(drugSynonyms_string) LIKE "%zoladex%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_246', 'tradeNames_string': 'Novgos, Zoladex, Zoladex la', 'drugName': 'Goserelin Acetate', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Gonadotropin-releasing hormone receptor agonist', 'linkedDiseasesDrug_string': 'Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Fallopian Tube Cancer (MONDO_0002158), Menopause (EFO_0003922), Salivary Gland Carcinoma (MONDO_0000521), Infertility (EFO_0000545), Male Breast Carcinoma (EFO_0006861), Metabolic Syndrome (EFO_0000195), Peritoneum Cancer (MONDO_0002087), Carcinoma (EFO_0000313), Prostate Carcinoma (EFO_0001663), Ovarian Cancer (MONDO_0008170), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305)', 'newLinkedTargets_string': 'GNRHR (ENSG00000109163)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1989, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2259', 'tradeNames_string': 'Zoladex', 'drugName': 'Goserelin', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Gonadotropin-releasing hormone receptor agonist', 'linkedDiseasesDrug_string': 'Uterine Fibroid (EFO_0000731), Prostate Carcinoma (EFO_0001663), Ovarian Cancer (MONDO_0008170), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Breast Neoplasm (EFO_0003869), Adenomyosis (EFO_1001757), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Premature Ovarian Insufficiency (HP_0008209), Male Breast Carcinoma (EFO_0006861), Endometriosis (EFO_0001065), Menopause (EFO_0003922), Salivary Gland Carcinoma (MONDO_0000521), Infertility (EFO_0000545), Peritoneum Cancer (MONDO_0002087), Carcinoma (EFO_0000313), Hodgkins Lymphoma (EFO_0000183), Invasive Lobular Carcinoma (EFO_0000553), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Metastatic Prostate Cancer (EFO_0000196), Metabolic Syndrome (EFO_0000195)', 'newLinkedTargets_string': 'GNRHR (ENSG00000109163)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1989, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.426 | Q22 | What is Savella? | Savella, also known generically as Milnacipran Hydrochloride, was approved by the FDA in 2009 to treat fibromyalgia. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%savella%" OR LOWER(tradeNames_string) LIKE "%savella%" OR LOWER(drugSynonyms_string) LIKE "%savella%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4225', 'tradeNames_string': 'Dalcipran, Ixel, Milnacipran hydrochloride, Savella, Toledomin', 'drugName': 'Milnacipran Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Norepinephrine transporter inhibitor', 'linkedDiseasesDrug_string': 'Fibromyalgia (EFO_0005687), Back Pain (HP_0003418)', 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A4 (ENSG00000108576)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2009, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4226', 'tradeNames_string': 'Dalcipran, Ixel, Milnacipran hydrochloride, Savella, Toledomin', 'drugName': 'Milnacipran Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Serotonin transporter inhibitor', 'linkedDiseasesDrug_string': 'Fibromyalgia (EFO_0005687), Back Pain (HP_0003418)', 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A4 (ENSG00000108576)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2009, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.180 | Q22 | What is Nocdurna? | Nocdurna, also known generically as Desmopressin Acetate, was approved by the FDA in 1978 to treat Central diabetes insipidus, Nasal congestion, hemorrhage, head injury, diabetes insipidus, enuresis, and von Willebrand disease (hereditary or acquired). It is a protein therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nocdurna%" OR LOWER(tradeNames_string) LIKE "%nocdurna%" OR LOWER(drugSynonyms_string) LIKE "%nocdurna%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2993', 'tradeNames_string': 'Concentraid, Ddavp, Ddavp (needs no refrigeration), Desmomelt, Desmopressin acetate, Desmopressin acetate (needs no refrigeration), Desmopressin acetate preservative free, Desmospray, Desmotabs, Minirin, Nocdurna, Noctiva, Nocutil, Noqdirna, Octim, Octostim, Presinex, Stimate, Stimate (needs no refrigeration)', 'drugName': 'Desmopressin Acetate', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Vasopressin receptor agonist', 'linkedDiseasesDrug_string': 'Intracerebral Hemorrhage (EFO_0005669), Enuresis (MONDO_0024290), Central Diabetes Insipidus (HP_0000863), Hemorrhage (MP_0001914), Hypertension (EFO_0000537), Ecchymosis (HP_0031364), Nasal Congestion (HP_0001742), Diabetes Insipidus (MONDO_0004782), Von Willebrand Disease (Hereditary Or Acquired) (MONDO_0024574), Head Injury (EFO_0009505)', 'newLinkedTargets_string': 'AVPR2 (ENSG00000126895), AVPR1A (ENSG00000166148), AVPR1B (ENSG00000198049)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1978, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.462 | Q22 | What is Genosyl? | Genosyl, also known generically as Nitric Oxide, was approved by the FDA in 1999 to treat Respiratory insufficiency, respiratory system disease, pulmonary arterial hypertension, respiratory failure, and pulmonary hypertension. It is a small molecule therapy that acts as a(n) activator. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%genosyl%" OR LOWER(tradeNames_string) LIKE "%genosyl%" OR LOWER(drugSynonyms_string) LIKE "%genosyl%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2884', 'tradeNames_string': 'Genosyl, Inomax', 'drugName': 'Nitric Oxide', 'drugMolecularType': 'Small molecule', 'drugActionType': 'activator', 'drugMechanismOfAction': 'Soluble guanylate cyclase activator', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Infection (EFO_0000544), Pulmonary Hypertension (MONDO_0005149), Pneumonia (EFO_0003106), Covid-19 (MONDO_0100096), Pulmonary Arterial Hypertension (EFO_0001361), St Elevation Myocardial Infarction (EFO_0008585), Pulmonary Embolism (EFO_0003827), Hypoxemia (EFO_0009447), Colorectal Carcinoma (EFO_1001951), Idiopathic Pulmonary Fibrosis (EFO_0000768), Lung Disease (EFO_0003818), Coronavirus Infectious Disease (EFO_0007224), Malaria (EFO_0001068), Bronchiolitis (HP_0011950), Myocardial Ischemia (EFO_1001375), Respiratory Insufficiency (HP_0002093), Tinea Pedis (EFO_0007512), Congestive Heart Failure (EFO_0000373), Persistent Fetal Circulation Syndrome (EFO_1001103), Neuropathic Pain (EFO_0005762), Brain Ischemia (MONDO_0005299), Sudden Cardiac Arrest (EFO_0004278), Acute Respiratory Distress Syndrome (EFO_1000637), Diabetic Foot (EFO_1001459), Decubitus Ulcer (EFO_0007067), Acute Myocardial Infarction (EFO_0008583), Sinusitis (EFO_0007486), Cardiac Arrest (EFO_0009492), Respiratory System Disease (EFO_0000684), Sepsis (HP_0100806), Premature Birth (EFO_0003917), Anemia (Phenotype) (EFO_0004272), Viral Pneumonia (EFO_0007541), Stroke (EFO_0000712), Sickle Cell Anemia (MONDO_0011382), Chronic Obstructive Pulmonary Disease (EFO_0000341), Inflammation (MP_0001845), Brain Injury (MONDO_0043510), Opioid Dependence (EFO_0005611), Varicose Ulcer (EFO_1001923), Congenital Heart Disease (EFO_0005207), Dyspnea (HP_0002094), Skin Ulcer (HP_0200042), Newborn Respiratory Distress Syndrome (EFO_1000644), Ischemia Reperfusion Injury (EFO_0002687), Respiratory Failure (EFO_0009686), Cutaneous Leishmaniasis (EFO_0005046), Acute Kidney Injury (HP_0001919), Cystic Fibrosis (MONDO_0009061), Bronchopulmonary Dysplasia (MONDO_0019091), Pneumonia, Aspiration (EFO_1001399), Severe Acute Respiratory Syndrome (EFO_0000694), Hypoxia (EFO_0009444)', 'newLinkedTargets_string': 'GUCY1B1 (ENSG00000061918), GUCY1B2 (ENSG00000123201), GUCY1A2 (ENSG00000152402), GUCY1A1 (ENSG00000164116)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1999, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.450 | Q22 | What is Ilevro? | Ilevro, also known generically as Nepafenac, was approved by the FDA in 2005 to treat inflammation, eye inflammation, and cataract. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ilevro%" OR LOWER(tradeNames_string) LIKE "%ilevro%" OR LOWER(drugSynonyms_string) LIKE "%ilevro%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5261', 'tradeNames_string': 'Ilevro, Nepafenac, Nevanac', 'drugName': 'Nepafenac', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Cyclooxygenase inhibitor', 'linkedDiseasesDrug_string': 'Cataract (MONDO_0005129), Eye Inflammation (EFO_0005752), Miosis (HP_0000616), Inflammation (MP_0001845), Macular Retinal Edema (MONDO_0003005)', 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2005, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.86 | Q22 | What is Latisse? | Latisse, also known generically as Bimatoprost, was approved by the FDA in 2001 to treat glaucoma, open-angle glaucoma, ocular hypertension, hypotrichosis, and hypotrichosis simplex. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%latisse%" OR LOWER(tradeNames_string) LIKE "%latisse%" OR LOWER(drugSynonyms_string) LIKE "%latisse%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_704', 'tradeNames_string': 'Bimatoprost, Durysta, Latisse, Lumigan', 'drugName': 'Bimatoprost', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Prostanoid FP receptor agonist', 'linkedDiseasesDrug_string': 'Androgenetic Alopecia (EFO_0004191), Vitiligo (EFO_0004208), Graves Ophthalmopathy (EFO_1001466), Alopecia (MONDO_0004907), Hypotrichosis (MONDO_0003037), Open-Angle Glaucoma (EFO_0004190), Hypotrichosis Simplex (MONDO_0018914), Ocular Hypertension (EFO_1001069), Glaucoma (MONDO_0005041)', 'newLinkedTargets_string': 'PTGFR (ENSG00000122420)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2001, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.459 | Q22 | What is Ofev? | Ofev, also known generically as Nintedanib Esylate, was approved by the FDA in 2014 to treat systemic scleroderma and idiopathic pulmonary fibrosis. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ofev%" OR LOWER(tradeNames_string) LIKE "%ofev%" OR LOWER(drugSynonyms_string) LIKE "%ofev%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5928', 'tradeNames_string': 'Ofev, Vargatef', 'drugName': 'Nintedanib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Fibroblast growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Genital Neoplasm, Female (EFO_1001331), Multiple Myeloma (EFO_0001378), Covid-19 (MONDO_0100096), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Urothelial Carcinoma (EFO_0008528), Appendix Cancer (MONDO_0001235), Squamous Cell Lung Carcinoma (EFO_0000708), Hereditary Hemorrhagic Telangiectasia (MONDO_0019180), Idiopathic Pulmonary Fibrosis (EFO_0000768), Endometrial Cancer (MONDO_0011962), Rectal Carcinoma (MONDO_0044937), Colorectal Carcinoma (EFO_1001951), Bronchiolitis Obliterans (EFO_0007183), Ovarian Cancer (MONDO_0008170), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Cervical Adenocarcinoma (EFO_0001416), Breast Cancer (MONDO_0007254), Gastric Adenocarcinoma (EFO_0000503), Lymphangioleiomyomatosis (MONDO_0011705), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Interstitial Lung Disease (EFO_0004244), Pancreatic Carcinoma (EFO_0002618), Anaplastic Oligodendroglioma (EFO_0002501), Lung Adenocarcinoma (EFO_0000571), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Renal Cell Carcinoma (EFO_0000681), Carcinoid Tumor (EFO_0004243), Salivary Gland Cancer (MONDO_0004669), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Systemic Scleroderma (EFO_0000717), Ovarian Neoplasm (EFO_0003893), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Malignant Pleural Mesothelioma (EFO_0000770), Sarcoma (EFO_0000691), Colon Adenocarcinoma (EFO_1001949), Pulmonary Fibrosis (EFO_0009448), Glioblastoma Multiforme (EFO_0000519)', 'newLinkedTargets_string': 'FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2014, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5929', 'tradeNames_string': 'Ofev, Vargatef', 'drugName': 'Nintedanib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Platelet-derived growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Genital Neoplasm, Female (EFO_1001331), Multiple Myeloma (EFO_0001378), Covid-19 (MONDO_0100096), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Urothelial Carcinoma (EFO_0008528), Appendix Cancer (MONDO_0001235), Squamous Cell Lung Carcinoma (EFO_0000708), Hereditary Hemorrhagic Telangiectasia (MONDO_0019180), Idiopathic Pulmonary Fibrosis (EFO_0000768), Endometrial Cancer (MONDO_0011962), Rectal Carcinoma (MONDO_0044937), Colorectal Carcinoma (EFO_1001951), Bronchiolitis Obliterans (EFO_0007183), Ovarian Cancer (MONDO_0008170), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Cervical Adenocarcinoma (EFO_0001416), Breast Cancer (MONDO_0007254), Gastric Adenocarcinoma (EFO_0000503), Lymphangioleiomyomatosis (MONDO_0011705), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Interstitial Lung Disease (EFO_0004244), Pancreatic Carcinoma (EFO_0002618), Anaplastic Oligodendroglioma (EFO_0002501), Lung Adenocarcinoma (EFO_0000571), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Renal Cell Carcinoma (EFO_0000681), Carcinoid Tumor (EFO_0004243), Salivary Gland Cancer (MONDO_0004669), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Systemic Scleroderma (EFO_0000717), Ovarian Neoplasm (EFO_0003893), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Malignant Pleural Mesothelioma (EFO_0000770), Sarcoma (EFO_0000691), Colon Adenocarcinoma (EFO_1001949), Pulmonary Fibrosis (EFO_0009448), Glioblastoma Multiforme (EFO_0000519)', 'newLinkedTargets_string': 'FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2014, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5930', 'tradeNames_string': 'Ofev, Vargatef', 'drugName': 'Nintedanib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Vascular endothelial growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Genital Neoplasm, Female (EFO_1001331), Multiple Myeloma (EFO_0001378), Covid-19 (MONDO_0100096), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Urothelial Carcinoma (EFO_0008528), Appendix Cancer (MONDO_0001235), Squamous Cell Lung Carcinoma (EFO_0000708), Hereditary Hemorrhagic Telangiectasia (MONDO_0019180), Idiopathic Pulmonary Fibrosis (EFO_0000768), Endometrial Cancer (MONDO_0011962), Rectal Carcinoma (MONDO_0044937), Colorectal Carcinoma (EFO_1001951), Bronchiolitis Obliterans (EFO_0007183), Ovarian Cancer (MONDO_0008170), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Cervical Adenocarcinoma (EFO_0001416), Breast Cancer (MONDO_0007254), Gastric Adenocarcinoma (EFO_0000503), Lymphangioleiomyomatosis (MONDO_0011705), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Interstitial Lung Disease (EFO_0004244), Pancreatic Carcinoma (EFO_0002618), Anaplastic Oligodendroglioma (EFO_0002501), Lung Adenocarcinoma (EFO_0000571), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Renal Cell Carcinoma (EFO_0000681), Carcinoid Tumor (EFO_0004243), Salivary Gland Cancer (MONDO_0004669), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Systemic Scleroderma (EFO_0000717), Ovarian Neoplasm (EFO_0003893), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Malignant Pleural Mesothelioma (EFO_0000770), Sarcoma (EFO_0000691), Colon Adenocarcinoma (EFO_1001949), Pulmonary Fibrosis (EFO_0009448), Glioblastoma Multiforme (EFO_0000519)', 'newLinkedTargets_string': 'FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2014, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4523', 'tradeNames_string': 'Ofev', 'drugName': 'Nintedanib Esylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Fibroblast growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Idiopathic Pulmonary Fibrosis (EFO_0000768), Systemic Scleroderma (EFO_0000717)', 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2014, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4524', 'tradeNames_string': 'Ofev', 'drugName': 'Nintedanib Esylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Platelet-derived growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Idiopathic Pulmonary Fibrosis (EFO_0000768), Systemic Scleroderma (EFO_0000717)', 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2014, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4525', 'tradeNames_string': 'Ofev', 'drugName': 'Nintedanib Esylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Vascular endothelial growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Idiopathic Pulmonary Fibrosis (EFO_0000768), Systemic Scleroderma (EFO_0000717)', 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2014, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.360 | Q22 | What is Fetzima? | Fetzima, also known generically as Levomilnacipran Hydrochloride, was approved by the FDA in 2013 to treat unipolar depression, fibromyalgia, and major depressive disorder. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fetzima%" OR LOWER(tradeNames_string) LIKE "%fetzima%" OR LOWER(drugSynonyms_string) LIKE "%fetzima%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5567', 'tradeNames_string': 'Fetzima', 'drugName': 'Levomilnacipran Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Serotonin transporter inhibitor', 'linkedDiseasesDrug_string': 'Fibromyalgia (EFO_0005687), Unipolar Depression (EFO_0003761), Major Depressive Disorder (MONDO_0002009), Ischemic Stroke (HP_0002140)', 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576), SLC6A2 (ENSG00000103546)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2013, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5568', 'tradeNames_string': 'Fetzima', 'drugName': 'Levomilnacipran Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Norepinephrine transporter inhibitor', 'linkedDiseasesDrug_string': 'Fibromyalgia (EFO_0005687), Unipolar Depression (EFO_0003761), Major Depressive Disorder (MONDO_0002009), Ischemic Stroke (HP_0002140)', 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576), SLC6A2 (ENSG00000103546)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2013, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4419', 'tradeNames_string': 'Fetzima', 'drugName': 'Levomilnacipran', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Serotonin transporter inhibitor', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Ischemic Stroke (HP_0002140), Nicotine Dependence (EFO_0003768), Fibromyalgia (EFO_0005687), Major Depressive Disorder (MONDO_0002009)', 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A4 (ENSG00000108576)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2013, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4420', 'tradeNames_string': 'Fetzima', 'drugName': 'Levomilnacipran', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Norepinephrine transporter inhibitor', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Ischemic Stroke (HP_0002140), Nicotine Dependence (EFO_0003768), Fibromyalgia (EFO_0005687), Major Depressive Disorder (MONDO_0002009)', 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A4 (ENSG00000108576)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2013, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.502 | Q22 | What is Farydak? | Farydak, also known generically as Panobinostat, was approved by the FDA in 2015 to treat cancer and neoplasm. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%farydak%" OR LOWER(tradeNames_string) LIKE "%farydak%" OR LOWER(drugSynonyms_string) LIKE "%farydak%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4906', 'tradeNames_string': 'Farydak', 'drugName': 'Panobinostat', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Histone deacetylase inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Primary Myelofibrosis (EFO_0002430), Non-Hodgkins Lymphoma (EFO_0005952), Skin Cancer (MONDO_0002898), Thyroid Carcinoma (EFO_0002892), Graft Versus Host Disease (MONDO_0013730), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Plasmacytoma (EFO_0006738), Metastatic Melanoma (EFO_0002617), Myelodysplastic Syndrome (EFO_0000198), Plasma Cell Leukemia (EFO_0006475), Colorectal Carcinoma (EFO_1001951), Polycythemia Vera (EFO_0002429), Gastric Cancer (MONDO_0001056), Chronic Myelogenous Leukemia (EFO_0000339), Prostate Adenocarcinoma (EFO_0000673), Malignant Colon Neoplasm (MONDO_0021063), Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Mantle Cell Lymphoma (EFO_1001469), Myelofibrosis (MONDO_0044903), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Chronic Myelomonocytic Leukemia (EFO_1001779), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Malignant Glioma (MONDO_0100342), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Sickle Cell Anemia (MONDO_0011382), Clear Cell Renal Carcinoma (EFO_0000349), Renal Cell Carcinoma (EFO_0000681), Waldenstrom Macroglobulinemia (EFO_0009441), Glioma (EFO_0005543), Cutaneous T-Cell Lymphoma (EFO_0002913), Hodgkins Lymphoma (EFO_0000183), Liver Cancer (MONDO_0002691), Rectum Cancer (EFO_1000657), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Hiv Infection (EFO_0000764), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Lung Cancer (MONDO_0008903), Nasopharyngeal Neoplasm (EFO_0004252), Non-Small Cell Lung Carcinoma (EFO_0003060), Classic Hodgkin Lymphoma (MONDO_0009348), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519)', 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5237', 'tradeNames_string': 'Farydak', 'drugName': 'Panobinostat Lactate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Histone deacetylase inhibitor', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378)', 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.582 | Q22 | What is Mayzent? | Mayzent, also known generically as Siponimod Fumarate, was approved by the FDA in 2019 to treat chronic progressive multiple sclerosis, relapsing-remitting multiple sclerosis, and multiple sclerosis. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mayzent%" OR LOWER(tradeNames_string) LIKE "%mayzent%" OR LOWER(drugSynonyms_string) LIKE "%mayzent%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4451', 'tradeNames_string': 'Mayzent', 'drugName': 'Siponimod Fumarate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Sphingosine 1-phosphate receptor Edg-1 agonist', 'linkedDiseasesDrug_string': 'Multiple Sclerosis (MONDO_0005301), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Chronic Progressive Multiple Sclerosis (EFO_0003840)', 'newLinkedTargets_string': 'S1PR1 (ENSG00000170989)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2019, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.81 | Q22 | What is Bepreve? | Bepreve, also known generically as Bepotastine Besylate, was approved by the FDA in 2009 to treat Pruritus and allergic conjunctivitis. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bepreve%" OR LOWER(tradeNames_string) LIKE "%bepreve%" OR LOWER(drugSynonyms_string) LIKE "%bepreve%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3215', 'tradeNames_string': 'Bepreve', 'drugName': 'Bepotastine Besylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Histamine H1 receptor antagonist', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Rhinitis, Allergic, Perennial (EFO_1001417), Pruritus (HP_0000989)', 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2009, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_6339', 'tradeNames_string': 'Bepreve', 'drugName': 'Bepotastine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Histamine H1 receptor antagonist', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Rhinitis, Allergic, Perennial (EFO_1001417), Seasonal Allergic Rhinitis (EFO_0003956), Pruritus (HP_0000989), Dermatitis (MONDO_0002406)', 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2009, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.24 | Q22 | What is Nesina? | Nesina, also known generically as Alogliptin Benzoate, was approved by the FDA in 2013 to treat type 2 diabetes mellitus. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nesina%" OR LOWER(tradeNames_string) LIKE "%nesina%" OR LOWER(drugSynonyms_string) LIKE "%nesina%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2469', 'tradeNames_string': 'Nesina', 'drugName': 'Alogliptin Benzoate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Dipeptidyl peptidase IV inhibitor', 'linkedDiseasesDrug_string': 'Type 2 Diabetes Mellitus (MONDO_0005148)', 'newLinkedTargets_string': 'DPP4 (ENSG00000197635)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2013, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.16 | Q22 | What is Proair Respiclick? | Proair Respiclick, also known generically as Albuterol Sulfate, was approved by the FDA in 1982 to treat Bronchospasm, chronic obstructive pulmonary disease, and asthma. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%proair respiclick%" OR LOWER(tradeNames_string) LIKE "%proair respiclick%" OR LOWER(drugSynonyms_string) LIKE "%proair respiclick%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6278', 'tradeNames_string': 'Accuneb, Albuterol sulfate, Proair, Proair digihaler, Proair hfa, Proair respiclick, Proventil, Proventil-hfa, Ventolin, Ventolin hfa, Ventolin rotacaps, Volmax, Vospire er', 'drugName': 'Albuterol Sulfate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Beta-2 adrenergic receptor agonist', 'linkedDiseasesDrug_string': 'Status Asthmaticus (EFO_0008590), Bronchospasm (HP_0025428), Asthma (MONDO_0004979), Chronic Obstructive Pulmonary Disease (EFO_0000341), Cardiovascular Disease (EFO_0000319), Adult Acute Respiratory Distress Syndrome (MONDO_0100130), Lung Disease (EFO_0003818)', 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1982, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.387 | Q22 | What is Lotemax Sm? | Lotemax Sm, also known generically as Loteprednol Etabonate, was approved by the FDA in 1998 to treat inflammation, eye inflammation, allergic conjunctivitis, anterior uveitis, and dry eye syndrome. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lotemax sm%" OR LOWER(tradeNames_string) LIKE "%lotemax sm%" OR LOWER(drugSynonyms_string) LIKE "%lotemax sm%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5556', 'tradeNames_string': 'Airex, Alrex, Eysuvis, Inveltys, Lotemax, Lotemax sm', 'drugName': 'Loteprednol Etabonate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucocorticoid receptor agonist', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Anterior Uveitis (EFO_1000811), Blepharitis (EFO_0009536), Cataract (MONDO_0005129), Ocular Pain (HP_0200026), Eye Inflammation (EFO_0005752), Inflammation (MP_0001845), Dry Eye Syndrome (EFO_1000906)', 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1998, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.296 | Q22 | What is Sancuso? | Sancuso, also known generically as Granisetron, was approved by the FDA in 1993 to treat Nausea and vomiting, Nausea, cancer, neoplasm, post operative nausea and vomiting, and Chemotherapy-induced nausea and vomiting. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sancuso%" OR LOWER(tradeNames_string) LIKE "%sancuso%" OR LOWER(drugSynonyms_string) LIKE "%sancuso%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2107', 'tradeNames_string': 'Kytril, Sancuso, Sustol', 'drugName': 'Granisetron', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Serotonin 3a (5-HT3a) receptor antagonist', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Sepsis (HP_0100806), Nausea (HP_0002018), Neoplasm (EFO_0000616), Chemotherapy-Induced Nausea And Vomiting (EFO_0006911), Nausea And Vomiting (HP_0002017), Lymphoma (EFO_0000574), Cervical Carcinoma (EFO_0001061), Post Operative Nausea And Vomiting (EFO_0004888), Mast-Cell Leukemia (EFO_0007359), Vomiting (HP_0002013), Gastroparesis (EFO_1000948), Pruritus (HP_0000989), Malignant Glioma (MONDO_0100342)', 'newLinkedTargets_string': 'HTR3A (ENSG00000166736)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1993, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.279 | Q22 | What is Gralise? | Gralise, also known generically as Gabapentin, was approved by the FDA in 1993 to treat Seizure, epilepsy, restless legs syndrome, neuralgia, and postherpetic neuralgia. It is a small molecule therapy that acts as a(n) modulator. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%gralise%" OR LOWER(tradeNames_string) LIKE "%gralise%" OR LOWER(drugSynonyms_string) LIKE "%gralise%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_142', 'tradeNames_string': 'Gabapentin, Gralise, Neurontin', 'drugName': 'Gabapentin', 'drugMolecularType': 'Small molecule', 'drugActionType': 'modulator', 'drugMechanismOfAction': 'Voltage-gated calcium channel modulator', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Head And Neck Carcinoma (MONDO_0002038), Carpal Tunnel Syndrome (EFO_0004143), Multiple Sclerosis (MONDO_0005301), Pain (EFO_0003843), Cannabis Dependence (EFO_0007191), Post Operative Nausea And Vomiting (EFO_0004888), Azoospermia (EFO_0000279), Injury (EFO_0000546), Reproductive System Disease (EFO_0000512), Hot Flashes (HP_0031217), Tremor (HP_0001337), Pelvic Organ Prolapse (EFO_0004710), Spontaneous Abortion (EFO_1001255), Lung Disease (EFO_0003818), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Rotator Cuff Tear (EFO_1001250), Nicotine Dependence (EFO_0003768), Intervertebral Disc Degeneration (HP_0008419), Dementia (HP_0000726), Neuropathic Pain (EFO_0005762), Fibromyalgia (EFO_0005687), Anxiety (EFO_0005230), Partial Epilepsy (EFO_0004263), Scoliosis (EFO_0004273), Epilepsy (EFO_0000474), Cicatricial Alopecia (EFO_1002028), Seizure (HP_0001250), Herpes Zoster (EFO_0006510), Autism Spectrum Disorder (EFO_0003756), Alcohol Withdrawal (EFO_0004777), Pruritus (HP_0000989), Alcohol Drinking (EFO_0004329), Restless Legs Syndrome (EFO_0004270), Sleep Disorder (EFO_0008568), Premature Birth (EFO_0003917), Oropharynx Cancer (EFO_1001931), Drug Dependence (EFO_0003890), Urinary Bladder Carcinoma (MONDO_0004986), Sickle Cell Anemia (MONDO_0011382), Delirium (EFO_0009267), Hyperemesis Gravidarum (EFO_1000971), Brain Injury (MONDO_0043510), Depressive Disorder (MONDO_0002050), Insomnia (EFO_0004698), Alcohol Dependence (MONDO_0007079), Opioid Dependence (EFO_0005611), Intervertebral Disc Displacement (EFO_1001800), Psychosis (EFO_0005407), Head And Neck Malignant Neoplasia (EFO_0006859), Hiv Infection (EFO_0000764), Diabetic Neuropathy (EFO_1000783), Postherpetic Neuralgia (MONDO_0041052), Post-Operative Sign Or Symptom (EFO_0005323), Chronic Pain (HP_0012532), Dyspepsia (EFO_0008533), Mucositis (EFO_1001898), Tinnitus (HP_0000360), Low Back Pain (HP_0003419), Vomiting (HP_0002013), Neuralgia (EFO_0009430), Schizophrenia (MONDO_0005090), Cirrhosis Of Liver (EFO_0001422)', 'newLinkedTargets_string': 'CACNA1H (ENSG00000196557), CACNA2D1 (ENSG00000153956), CACNA1C (ENSG00000151067), CACNA2D3 (ENSG00000157445), CACNA1S (ENSG00000081248), CACNA2D2 (ENSG00000007402), CACNA1D (ENSG00000157388), CACNA1A (ENSG00000141837), CACNA1B (ENSG00000148408), CACNA1G (ENSG00000006283), CACNA2D4 (ENSG00000151062), CACNA1I (ENSG00000100346), CACNA1F (ENSG00000102001), CACNA1E (ENSG00000198216), CACNB4 (ENSG00000182389), CACNB2 (ENSG00000165995), CACNB1 (ENSG00000067191), CACNB3 (ENSG00000167535), CACNG7 (ENSG00000105605), CACNG5 (ENSG00000075429), CACNG2 (ENSG00000166862), CACNG4 (ENSG00000075461), CACNG8 (ENSG00000142408), CACNG3 (ENSG00000006116), CACNG6 (ENSG00000130433), CACNG1 (ENSG00000108878)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1993, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.660 | Q22 | What is Lysteda? | Lysteda, also known generically as Tranexamic Acid, was approved by the FDA in 1986 to treat Menorrhagia, hemorrhage, and hemophilia A. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lysteda%" OR LOWER(tradeNames_string) LIKE "%lysteda%" OR LOWER(drugSynonyms_string) LIKE "%lysteda%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5780', 'tradeNames_string': 'Cyklo-f heavy period relief, Cyklokapron, Exacyl, Lysteda, Menstralite, Tranexamic acid', 'drugName': 'Tranexamic Acid', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Plasminogen inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Intracranial Subdural Hematoma (EFO_1001801), Coronary Artery Disease (EFO_0001645), Hip Fracture (EFO_0003964), Hemorrhage (MP_0001914), Malignant Bone Neoplasm (EFO_1000350), Pain (EFO_0003843), Covid-19 (MONDO_0100096), Uterine Fibroid (EFO_0000731), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Femoral Neck Fracture (EFO_1001792), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Central Nervous System Cancer (EFO_0000326), Shoulder Pain (HP_0030834), Injury (EFO_0000546), Abdominal Aortic Aneurysm (EFO_0004214), Placenta Praevia (EFO_0007442), Hypotension (EFO_0005251), Hereditary Hemorrhagic Telangiectasia (MONDO_0019180), Lymphoid Neoplasm (EFO_0001642), Pelvic Organ Prolapse (EFO_0004710), Astrocytoma (EFO_0000272), Intracerebral Hemorrhage (EFO_0005669), Septic Shock (EFO_0006834), Intervertebral Disc Degeneration (HP_0008419), Osteoarthritis, Knee (EFO_0004616), Freckles (EFO_0003963), Female Reproductive System Neoplasm (MONDO_0021148), Scoliosis (EFO_0004273), Hemophilia A (MONDO_0010602), Arthropathy (HP_0003040), Bone Fracture (EFO_0003931), Ileus (MONDO_0004567), Nasal Cavity Polyp (EFO_1000391), Thrombocytopenia (HP_0001873), Hematoma (EFO_0010680), Sepsis (HP_0100806), Anemia (Phenotype) (EFO_0004272), Shock (HP_0031273), Back Pain (HP_0003418), Subarachnoid Hemorrhage (EFO_0000713), Joint Disease (EFO_1000999), Brain Neoplasm (EFO_0003833), Inflammation (MP_0001845), Epistaxis (EFO_0003895), Brain Injury (MONDO_0043510), Skin Neoplasm (EFO_0004198), Postpartum Hemorrhage (EFO_0009579), Hemoptysis (HP_0002105), Menorrhagia (HP_0000132), Osteoarthritis (MONDO_0005178), Placenta Accreta (EFO_0007440), Meningioma (MONDO_0016642), Gastrointestinal Hemorrhage (HP_0002239), Urinary Bladder Cancer (MONDO_0001187), Blood Coagulation Disease (EFO_0009314), Shoulder Impingement Syndrome (EFO_1001178), Hereditary Angioedema (MONDO_0019623)', 'newLinkedTargets_string': 'PLG (ENSG00000122194)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1986, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.318 | Q22 | What is Zyclara? | Zyclara, also known generically as Imiquimod, was approved by the FDA in 1997 to treat viral disease, actinic keratosis, basal cell carcinoma, keratosis, and skin basal cell carcinoma. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%zyclara%" OR LOWER(tradeNames_string) LIKE "%zyclara%" OR LOWER(drugSynonyms_string) LIKE "%zyclara%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1394', 'tradeNames_string': 'Aldara, Imiquimod, Zyclara', 'drugName': 'Imiquimod', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Toll-like receptor 7 agonist', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Medulloblastoma (EFO_0002939), Chronic Lymphocytic Leukemia (EFO_0000095), Plasmodium Falciparum Malaria (EFO_0007444), Keratosis (EFO_1000720), Intraepithelial Neoplasia (MONDO_0024474), Anogenital Venereal Wart (EFO_0007147), Kidney Failure (EFO_1002048), Anal Neoplasm (EFO_0003835), Familial Multiple Nevi Flammei (MONDO_0008094), Colorectal Carcinoma (EFO_1001951), Mouth Neoplasm (EFO_0003868), Ovarian Cancer (MONDO_0008170), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Avian Influenza (EFO_0005222), Hepatitis B Virus Infection (EFO_0004197), Bone Sarcoma (MONDO_0021054), Acute Lymphoblastic Leukemia (EFO_0000220), Vulvar Intraepithelial Neoplasia (EFO_0002627), Cervical Carcinoma (EFO_0001061), Basal Cell Carcinoma (EFO_0004193), Malignant Glioma (MONDO_0100342), Keloid (EFO_0004212), Cervical Intraepithelial Neoplasia (MONDO_0022394), Viral Disease (EFO_0000763), Human Papilloma Virus Infection (EFO_0001668), Skin Basal Cell Carcinoma (MONDO_0005341), Actinic Keratosis (EFO_0002496), Soft Tissue Sarcoma (EFO_1001968), Cheilitis (MONDO_0002102), Hemangioma (EFO_1000635), Influenza (EFO_0007328), Ependymoma (EFO_1000028), Cutaneous T-Cell Lymphoma (EFO_0002913), Cutaneous Melanoma (EFO_0000389), Cervical Cancer (MONDO_0002974), Extramammary Paget Disease (EFO_1000249), Localised Scleroderma (EFO_1001361), Brain Cancer (MONDO_0001657), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Squamous Cell Carcinoma (EFO_0000707), Leukemia (EFO_0000565), Fallopian Tube Cancer (MONDO_0002158), Glioblastoma Multiforme (EFO_0000519), Non-Small Cell Lung Carcinoma (EFO_0003060), Melanoma (EFO_0000756), Cutaneous Leishmaniasis (EFO_0005046), Squamous Cell Intraepithelial Neoplasia (MONDO_0024475), Lentigo (MONDO_0021582), Cirrhosis Of Liver (EFO_0001422)', 'newLinkedTargets_string': 'TLR7 (ENSG00000196664)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1997, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.526 | Q22 | What is Trulance? | Trulance, also known generically as Plecanatide, was approved by the FDA in 2017 to treat Constipation. It is a protein therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%trulance%" OR LOWER(tradeNames_string) LIKE "%trulance%" OR LOWER(drugSynonyms_string) LIKE "%trulance%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5758', 'tradeNames_string': 'Trulance', 'drugName': 'Plecanatide', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Heat-stable enterotoxin receptor agonist', 'linkedDiseasesDrug_string': 'Constipation (HP_0002019), Irritable Bowel Syndrome (EFO_0000555)', 'newLinkedTargets_string': 'GUCY2C (ENSG00000070019)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2017, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.140 | Q22 | What is Sensipar? | Sensipar, also known generically as Cinacalcet, was approved by the FDA in 2004 to treat parathyroid disease. It is a small molecule therapy that acts as a(n) positive allosteric modulator. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sensipar%" OR LOWER(tradeNames_string) LIKE "%sensipar%" OR LOWER(drugSynonyms_string) LIKE "%sensipar%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_841', 'tradeNames_string': 'Mimpara, Sensipar', 'drugName': 'Cinacalcet Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'positive allosteric modulator', 'drugMechanismOfAction': 'Calcium sensing receptor positive allosteric modulator', 'linkedDiseasesDrug_string': 'Chronic Kidney Disease (EFO_0003884), Secondary Hyperparathyroidism (EFO_1001173), Parathyroid Gland Carcinoma (EFO_1000456), Carcinoma (EFO_0000313), Prostate Adenocarcinoma (EFO_0000673)', 'newLinkedTargets_string': 'CASR (ENSG00000036828)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2004, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_247', 'tradeNames_string': 'Sensipar', 'drugName': 'Cinacalcet', 'drugMolecularType': 'Small molecule', 'drugActionType': 'positive allosteric modulator', 'drugMechanismOfAction': 'Calcium sensing receptor positive allosteric modulator', 'linkedDiseasesDrug_string': 'Chronic Kidney Disease (EFO_0003884), Memory Impairment (EFO_0001072), Secondary Hyperparathyroidism (EFO_1001173), Hyperparathyroidism (EFO_0008506), Parathyroid Gland Carcinoma (EFO_1000456), Primary Hyperparathyroidism (EFO_0008519), Parathyroid Disease (EFO_0005754), Renal Osteodystrophy (EFO_1001152), Hypophosphatemic Rickets (MONDO_0024300), Carcinoma (EFO_0000313), Prostate Adenocarcinoma (EFO_0000673)', 'newLinkedTargets_string': 'CASR (ENSG00000036828)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2004, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.492 | Q22 | What is Upneeq? | Upneeq, also known generically as Oxymetazoline Hydrochloride, was approved by the FDA in 1986 to treat Nasal congestion, seasonal allergic rhinitis, allergic rhinitis, common cold, sinusitis, rosacea, and ptosis. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%upneeq%" OR LOWER(tradeNames_string) LIKE "%upneeq%" OR LOWER(drugSynonyms_string) LIKE "%upneeq%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_543', 'tradeNames_string': 'Afrazine, Ocuclear, Rhofade, Upneeq, Visine, Visine l.r.', 'drugName': 'Oxymetazoline Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Adrenergic receptor alpha agonist', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Sinusitis (EFO_0007486), Rosacea (EFO_1000760), Common Cold (EFO_0007214), Presbyopia (MONDO_0001330), Seasonal Allergic Rhinitis (EFO_0003956), Erythema (HP_0010783), Allergic Rhinitis (EFO_0005854), Nasal Congestion (HP_0001742), Ptosis (MONDO_0000728)', 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1986, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.490 | Q22 | What is Roxybond? | Roxybond, also known generically as Oxycodone Hydrochloride, was approved by the FDA in 1950 to treat Chronic pain and pain. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%roxybond%" OR LOWER(tradeNames_string) LIKE "%roxybond%" OR LOWER(drugSynonyms_string) LIKE "%roxybond%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4049', 'tradeNames_string': 'Abtard, Candox, Carexil, Dolocodon pr, Leveraxo, Longtec, Lynlor, Oxaydo, Oxecta, Oxeltra, Oxycodone hydrochloride, Oxycontin, Oxylan, Oxynorm, Reltebon, Roxicodone, Roxybond, Shortec, Zomestine', 'drugName': 'Oxycodone Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Mu opioid receptor agonist', 'linkedDiseasesDrug_string': 'Osteoarthritis, Hip (EFO_1000786), Pain (EFO_0003843), Chronic Pain (HP_0012532), Osteoarthritis, Knee (EFO_0004616), Low Back Pain (HP_0003419)', 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1950, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.34 | Q22 | What is Katerzia? | Katerzia, also known generically as Amlodipine Benzoate, was approved by the FDA in 2019 to treat diabetes mellitus, hypertension, myocardial infarction, stroke, coronary artery disease, and heart failure. It is a small molecule therapy that acts as a(n) blocker. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%katerzia%" OR LOWER(tradeNames_string) LIKE "%katerzia%" OR LOWER(drugSynonyms_string) LIKE "%katerzia%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5167', 'tradeNames_string': 'Katerzia', 'drugName': 'Amlodipine Benzoate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Voltage-gated L-type calcium channel blocker', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Coronary Artery Disease (EFO_0001645), Stroke (EFO_0000712), Heart Failure (EFO_0003144), Hypertension (EFO_0000537), Myocardial Infarction (EFO_0000612)', 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2019, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.669 | Q22 | What is Aklief? | Aklief, also known generically as Trifarotene, was approved by the FDA in 2019 to treat acne. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%aklief%" OR LOWER(tradeNames_string) LIKE "%aklief%" OR LOWER(drugSynonyms_string) LIKE "%aklief%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4733', 'tradeNames_string': 'Aklief', 'drugName': 'Trifarotene', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Retinoic acid receptor gamma agonist', 'linkedDiseasesDrug_string': 'Lamellar Ichthyosis (MONDO_0017778), Acne (EFO_0003894), Lymphoma (EFO_0000574)', 'newLinkedTargets_string': 'RARG (ENSG00000172819)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2019, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.261 | Q22 | What is Onsolis? | Onsolis, also known generically as Fentanyl Citrate, was approved by the FDA in 1968 to treat cancer and pain. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%onsolis%" OR LOWER(tradeNames_string) LIKE "%onsolis%" OR LOWER(drugSynonyms_string) LIKE "%onsolis%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_733', 'tradeNames_string': 'Abstral, Actiq, Fentanyl, Fentanyl citrate, Fentanyl citrate preservative free, Fentora, Lazanda, Onsolis, Sublimaze, Sublimaze preservative free, Thalamonal', 'drugName': 'Fentanyl Citrate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Mu opioid receptor agonist', 'linkedDiseasesDrug_string': 'Shortness Of Breath (EFO_0009727), Cancer (MONDO_0004992), Dyspnea (HP_0002094), Pulpitis (EFO_1001139), Pain (EFO_0003843), Chronic Pain (HP_0012532), Neuropathic Pain (EFO_0005762), Interstitial Lung Disease (EFO_0004244), Low Back Pain (HP_0003419), Injury (EFO_0000546)', 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1968, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.10 | Q22 | What is Gilotrif? | Gilotrif, also known generically as Afatinib, was approved by the FDA in 2013 to treat cancer and neoplasm. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%gilotrif%" OR LOWER(tradeNames_string) LIKE "%gilotrif%" OR LOWER(drugSynonyms_string) LIKE "%gilotrif%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1042', 'tradeNames_string': 'Gilotrif, Giotrif', 'drugName': 'Afatinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Epidermal growth factor receptor erbB1 inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Liver Disease (EFO_0001421), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Prostate Adenocarcinoma (EFO_0000673), Breast Neoplasm (EFO_0003869), Uterine Neoplasm (EFO_0003859), Breast Cancer (MONDO_0007254), Colorectal Neoplasm (EFO_0004142), Gallbladder Carcinoma (EFO_1001956), Endometriosis (EFO_0001065), Renal Insufficiency (HP_0000083), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Lung Neoplasm (MONDO_0021117), Glioma (EFO_0005543), Brain Cancer (MONDO_0001657), Metastatic Neoplasm (EFO_0009709), Urogenital Neoplasm (EFO_0003863), Lung Cancer (MONDO_0008903), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Esophageal Squamous Cell Carcinoma (EFO_0005922), Chordoma (MONDO_0008978), Non-Small Cell Lung Carcinoma (EFO_0003060), Glioblastoma Multiforme (EFO_0000519)', 'newLinkedTargets_string': 'ERBB4 (ENSG00000178568), EGFR (ENSG00000146648), ERBB2 (ENSG00000141736)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2013, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1043', 'tradeNames_string': 'Gilotrif, Giotrif', 'drugName': 'Afatinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Receptor protein-tyrosine kinase erbB-2 inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Liver Disease (EFO_0001421), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Prostate Adenocarcinoma (EFO_0000673), Breast Neoplasm (EFO_0003869), Uterine Neoplasm (EFO_0003859), Breast Cancer (MONDO_0007254), Colorectal Neoplasm (EFO_0004142), Gallbladder Carcinoma (EFO_1001956), Endometriosis (EFO_0001065), Renal Insufficiency (HP_0000083), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Lung Neoplasm (MONDO_0021117), Glioma (EFO_0005543), Brain Cancer (MONDO_0001657), Metastatic Neoplasm (EFO_0009709), Urogenital Neoplasm (EFO_0003863), Lung Cancer (MONDO_0008903), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Esophageal Squamous Cell Carcinoma (EFO_0005922), Chordoma (MONDO_0008978), Non-Small Cell Lung Carcinoma (EFO_0003060), Glioblastoma Multiforme (EFO_0000519)', 'newLinkedTargets_string': 'ERBB4 (ENSG00000178568), EGFR (ENSG00000146648), ERBB2 (ENSG00000141736)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2013, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1044', 'tradeNames_string': 'Gilotrif, Giotrif', 'drugName': 'Afatinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Receptor protein-tyrosine kinase erbB-4 inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Liver Disease (EFO_0001421), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Prostate Adenocarcinoma (EFO_0000673), Breast Neoplasm (EFO_0003869), Uterine Neoplasm (EFO_0003859), Breast Cancer (MONDO_0007254), Colorectal Neoplasm (EFO_0004142), Gallbladder Carcinoma (EFO_1001956), Endometriosis (EFO_0001065), Renal Insufficiency (HP_0000083), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Lung Neoplasm (MONDO_0021117), Glioma (EFO_0005543), Brain Cancer (MONDO_0001657), Metastatic Neoplasm (EFO_0009709), Urogenital Neoplasm (EFO_0003863), Lung Cancer (MONDO_0008903), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Esophageal Squamous Cell Carcinoma (EFO_0005922), Chordoma (MONDO_0008978), Non-Small Cell Lung Carcinoma (EFO_0003060), Glioblastoma Multiforme (EFO_0000519)', 'newLinkedTargets_string': 'ERBB4 (ENSG00000178568), EGFR (ENSG00000146648), ERBB2 (ENSG00000141736)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2013, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2558', 'tradeNames_string': 'Gilotrif', 'drugName': 'Afatinib Dimaleate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Epidermal growth factor receptor erbB1 inhibitor', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Non-Small Cell Lung Carcinoma (EFO_0003060)', 'newLinkedTargets_string': 'ERBB4 (ENSG00000178568), EGFR (ENSG00000146648), ERBB2 (ENSG00000141736)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2013, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2559', 'tradeNames_string': 'Gilotrif', 'drugName': 'Afatinib Dimaleate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Receptor protein-tyrosine kinase erbB-2 inhibitor', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Non-Small Cell Lung Carcinoma (EFO_0003060)', 'newLinkedTargets_string': 'ERBB4 (ENSG00000178568), EGFR (ENSG00000146648), ERBB2 (ENSG00000141736)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2013, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2560', 'tradeNames_string': 'Gilotrif', 'drugName': 'Afatinib Dimaleate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Receptor protein-tyrosine kinase erbB-4 inhibitor', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Non-Small Cell Lung Carcinoma (EFO_0003060)', 'newLinkedTargets_string': 'ERBB4 (ENSG00000178568), EGFR (ENSG00000146648), ERBB2 (ENSG00000141736)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2013, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.23 | Q22 | What is Tekturna? | Tekturna, also known generically as Aliskiren Fumarate, was approved by the FDA in 2007 to treat hypertension and stroke. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tekturna%" OR LOWER(tradeNames_string) LIKE "%tekturna%" OR LOWER(drugSynonyms_string) LIKE "%tekturna%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4221', 'tradeNames_string': 'Tekturna', 'drugName': 'Aliskiren Fumarate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Renin inhibitor', 'linkedDiseasesDrug_string': 'Stroke (EFO_0000712), Hypertension (EFO_0000537)', 'newLinkedTargets_string': 'REN (ENSG00000143839)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2007, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.550 | Q22 | What is Nurtec Odt? | Nurtec Odt, also known generically as Rimegepant Sulfate, was approved by the FDA in 2020 to treat migraine disorder. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nurtec odt%" OR LOWER(tradeNames_string) LIKE "%nurtec odt%" OR LOWER(drugSynonyms_string) LIKE "%nurtec odt%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3190', 'tradeNames_string': 'Nurtec odt', 'drugName': 'Rimegepant Sulfate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Calcitonin gene-related peptide type 1 receptor antagonist', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277)', 'newLinkedTargets_string': 'CALCRL (ENSG00000064989)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2020, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.225 | Q22 | What is Emerphed? | Emerphed, also known generically as Ephedrine Sulfate, was approved by the FDA in 2016 to treat Nasal congestion, seasonal allergic rhinitis, hypotension, common cold, and asthma. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%emerphed%" OR LOWER(tradeNames_string) LIKE "%emerphed%" OR LOWER(drugSynonyms_string) LIKE "%emerphed%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4865', 'tradeNames_string': 'Akovaz, Corphedra, Emerphed, Expansyl, Franol plus, Franol-plus, Isofedrol', 'drugName': 'Ephedrine Sulfate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Adrenergic receptor agonist', 'linkedDiseasesDrug_string': 'Nasal Congestion (HP_0001742), Asthma (MONDO_0004979), Common Cold (EFO_0007214), Seasonal Allergic Rhinitis (EFO_0003956), Hypotension (EFO_0005251)', 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), ADRB3 (ENSG00000188778)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2016, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.410 | Q22 | What is Riomet Er? | Riomet Er, also known generically as Metformin Hydrochloride, was approved by the FDA in 1995 to treat diabetes mellitus and type 2 diabetes mellitus. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%riomet er%" OR LOWER(tradeNames_string) LIKE "%riomet er%" OR LOWER(drugSynonyms_string) LIKE "%riomet er%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1887', 'tradeNames_string': 'Bolamyn sr, Diagemet xl, Fortamet, Glucamet 500, Glucamet 850, Glucient sr, Glucophage, Glucophage sr, Glucophage xr, Glumetza, Glyformin, Janumet, Ledermetin, Metabet sr, Metformin hydrochloride, Metsol, Milform, Orabet, Riomet, Riomet er, Sukkarto sr', 'drugName': 'Metformin Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Multiple Myeloma (EFO_0001378), Fanconi Anemia (MONDO_0019391), Obesity (EFO_0001073), Lung Carcinoma (EFO_0001071), Prostate Carcinoma (EFO_0001663), Malignant Colon Neoplasm (MONDO_0021063), Prostate Adenocarcinoma (EFO_0000673), Ascites (HP_0001541), Gliosarcoma (EFO_1001465), Polycystic Ovary Syndrome (EFO_0000660), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Diabetic Foot (EFO_1001459), Oral Squamous Cell Carcinoma (EFO_0000199), Pleural Effusion (EFO_0009637), Endometrial Carcinoma (EFO_1001512), Pancreatic Carcinoma (EFO_0002618), Lung Adenocarcinoma (EFO_0000571), Gestational Diabetes (EFO_0004593), Peritoneum Cancer (MONDO_0002087), Hyperinsulinemia (HP_0000842), Inflammation (MP_0001845), Stargardt Disease (MONDO_0019353), Breast Ductal Carcinoma In Situ (EFO_0000432), Endometrioid Carcinoma (EFO_0000466), Chronic Kidney Disease (EFO_0003884), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Diabetic Neuropathy (EFO_1000783), Ovarian Serous Cystadenocarcinoma (EFO_1000043), Heart Failure (EFO_0003144), Non-Small Cell Lung Carcinoma (EFO_0003060), Metabolic Syndrome (EFO_0000195), Type 2 Diabetes Mellitus (MONDO_0005148)', 'newLinkedTargets_string': 'GPD2 (ENSG00000115159), MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1995, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1888', 'tradeNames_string': 'Bolamyn sr, Diagemet xl, Fortamet, Glucamet 500, Glucamet 850, Glucient sr, Glucophage, Glucophage sr, Glucophage xr, Glumetza, Glyformin, Janumet, Ledermetin, Metabet sr, Metformin hydrochloride, Metsol, Milform, Orabet, Riomet, Riomet er, Sukkarto sr', 'drugName': 'Metformin Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Mitochondrial complex I (NADH dehydrogenase) inhibitor', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Multiple Myeloma (EFO_0001378), Fanconi Anemia (MONDO_0019391), Obesity (EFO_0001073), Lung Carcinoma (EFO_0001071), Prostate Carcinoma (EFO_0001663), Malignant Colon Neoplasm (MONDO_0021063), Prostate Adenocarcinoma (EFO_0000673), Ascites (HP_0001541), Gliosarcoma (EFO_1001465), Polycystic Ovary Syndrome (EFO_0000660), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Diabetic Foot (EFO_1001459), Oral Squamous Cell Carcinoma (EFO_0000199), Pleural Effusion (EFO_0009637), Endometrial Carcinoma (EFO_1001512), Pancreatic Carcinoma (EFO_0002618), Lung Adenocarcinoma (EFO_0000571), Gestational Diabetes (EFO_0004593), Peritoneum Cancer (MONDO_0002087), Hyperinsulinemia (HP_0000842), Inflammation (MP_0001845), Stargardt Disease (MONDO_0019353), Breast Ductal Carcinoma In Situ (EFO_0000432), Endometrioid Carcinoma (EFO_0000466), Chronic Kidney Disease (EFO_0003884), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Diabetic Neuropathy (EFO_1000783), Ovarian Serous Cystadenocarcinoma (EFO_1000043), Heart Failure (EFO_0003144), Non-Small Cell Lung Carcinoma (EFO_0003060), Metabolic Syndrome (EFO_0000195), Type 2 Diabetes Mellitus (MONDO_0005148)', 'newLinkedTargets_string': 'GPD2 (ENSG00000115159), MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1995, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.691 | Q22 | What is Viltepso? | Viltepso, also known generically as Viltolarsen, was approved by the FDA in 2020 to treat Duchenne muscular dystrophy and muscular dystrophy. It is a oligonucleotide therapy that acts as a(n) positive modulator. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%viltepso%" OR LOWER(tradeNames_string) LIKE "%viltepso%" OR LOWER(drugSynonyms_string) LIKE "%viltepso%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2014', 'tradeNames_string': 'Viltepso', 'drugName': 'Viltolarsen', 'drugMolecularType': 'Oligonucleotide', 'drugActionType': 'positive modulator', 'drugMechanismOfAction': 'Dystrophin pre-mRNA positive modulator', 'linkedDiseasesDrug_string': 'Muscular Dystrophy (MONDO_0020121), Duchenne Muscular Dystrophy (MONDO_0010679)', 'newLinkedTargets_string': 'DMD (ENSG00000198947)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2020, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.340 | Q22 | What is Reyvow? | Reyvow, also known generically as Lasmiditan Succinate, was approved by the FDA in 2020 to treat migraine disorder. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%reyvow%" OR LOWER(tradeNames_string) LIKE "%reyvow%" OR LOWER(drugSynonyms_string) LIKE "%reyvow%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1894', 'tradeNames_string': 'Reyvow', 'drugName': 'Lasmiditan Succinate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Serotonin 1f (5-HT1f) receptor agonist', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277)', 'newLinkedTargets_string': 'HTR1F (ENSG00000179097)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2020, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.87 | Q22 | What is Lumigan? | Lumigan, also known generically as Bimatoprost, was approved by the FDA in 2001 to treat glaucoma, open-angle glaucoma, ocular hypertension, hypotrichosis, and hypotrichosis simplex. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lumigan%" OR LOWER(tradeNames_string) LIKE "%lumigan%" OR LOWER(drugSynonyms_string) LIKE "%lumigan%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_704', 'tradeNames_string': 'Bimatoprost, Durysta, Latisse, Lumigan', 'drugName': 'Bimatoprost', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Prostanoid FP receptor agonist', 'linkedDiseasesDrug_string': 'Androgenetic Alopecia (EFO_0004191), Vitiligo (EFO_0004208), Graves Ophthalmopathy (EFO_1001466), Alopecia (MONDO_0004907), Hypotrichosis (MONDO_0003037), Open-Angle Glaucoma (EFO_0004190), Hypotrichosis Simplex (MONDO_0018914), Ocular Hypertension (EFO_1001069), Glaucoma (MONDO_0005041)', 'newLinkedTargets_string': 'PTGFR (ENSG00000122420)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2001, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.341 | Q22 | What is Xelpros? | Xelpros, also known generically as Latanoprost, was approved by the FDA in 1996 to treat glaucoma, hypertension, open-angle glaucoma, and ocular hypertension. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%xelpros%" OR LOWER(tradeNames_string) LIKE "%xelpros%" OR LOWER(drugSynonyms_string) LIKE "%xelpros%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_318', 'tradeNames_string': 'Latanoprost, Monopost, Xalatan, Xelpros', 'drugName': 'Latanoprost', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Prostanoid FP receptor agonist', 'linkedDiseasesDrug_string': 'Vitiligo (EFO_0004208), Open-Angle Glaucoma (EFO_0004190), Hypertension (EFO_0000537), Ocular Hypertension (EFO_1001069), Meniere Disease (EFO_0006862), Glaucoma (MONDO_0005041)', 'newLinkedTargets_string': 'PTGFR (ENSG00000122420)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1996, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.251 | Q22 | What is Antara (Micronized)? | Antara (Micronized), also known generically as Fenofibrate, was approved by the FDA in 1993 to treat Abnormal circulating lipid concentration, Hypercholesterolemia, cardiovascular disease, diabetes mellitus, hypothyroidism, and type 2 diabetes mellitus. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%antara (micronized)%" OR LOWER(tradeNames_string) LIKE "%antara (micronized)%" OR LOWER(drugSynonyms_string) LIKE "%antara (micronized)%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1497', 'tradeNames_string': 'Antara, Antara (micronized), Fenofibrate, Fenofibrate (micronized), Fenogal, Fenoglide, Lipantil, Lipantil micro 200, Lipantil micro 267, Lipantil micro 67, Lipidil, Lipofen, Supralip 160, Tricor, Tricor (micronized), Triglide', 'drugName': 'Fenofibrate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Peroxisome proliferator-activated receptor alpha agonist', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Hyperlipidemia (MONDO_0021187), Hypertriglyceridemia (EFO_0004211), Coronary Artery Disease (EFO_0001645), Multiple Myeloma (EFO_0001378), Combined Hyperlipidemia (Orphanet_79211), Obesity (EFO_0001073), Hypothyroidism (EFO_0004705), Metabolic Disease (EFO_0000589), Primary Biliary Cirrhosis (EFO_1001486), Diabetic Retinopathy (EFO_0003770), Huntington Disease (MONDO_0007739), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Non-Alcoholic Steatohepatitis (EFO_1001249), Disorder Of Lipid Metabolism (Orphanet_309005), Abnormal Circulating Lipid Concentration (HP_0003119), Hypercholesterolemia (HP_0003124), Hiv-1 Infection (EFO_0000180), Hyperlipoproteinemia (MONDO_0037748), Alcohol Dependence (MONDO_0007079), Hyperlipoproteinemia Type 3 (MONDO_0018473), Lipodystrophy (EFO_1000727), Diabetic Nephropathy (EFO_0000401), Burn (EFO_0009516), Metabolic Syndrome (EFO_0000195), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914), Sclerosing Cholangitis (EFO_0004268)', 'newLinkedTargets_string': 'PPARA (ENSG00000186951)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1993, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.589 | Q22 | What is Odomzo? | Odomzo, also known generically as Sonidegib Phosphate, was approved by the FDA in 2015 to treat basal cell carcinoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%odomzo%" OR LOWER(tradeNames_string) LIKE "%odomzo%" OR LOWER(drugSynonyms_string) LIKE "%odomzo%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3933', 'tradeNames_string': 'Odomzo', 'drugName': 'Sonidegib Phosphate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Smoothened homolog inhibitor', 'linkedDiseasesDrug_string': 'Basal Cell Carcinoma (EFO_0004193)', 'newLinkedTargets_string': 'SMO (ENSG00000128602)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.627 | Q22 | What is Androgel? | Androgel, also known generically as Testosterone, was approved by the FDA in 1972 to treat Hypogonadotropic hypogonadism, Klinefelter's syndrome, orchitis, hypogonadism, and hypogonadotropic hypogonadism. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%androgel%" OR LOWER(tradeNames_string) LIKE "%androgel%" OR LOWER(drugSynonyms_string) LIKE "%androgel%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5308', 'tradeNames_string': 'Androderm, Androgel, Androgel 1%, Andropatch, Axiron, Fortesta, Intrinsa, Natesto, Striant, Striant sr, Testim, Testim 1%, Testoderm, Testoderm tts, Testogel, Testopatch, Testopel, Testoral, Testosterone, Tostran, Vogelxo', 'drugName': 'Testosterone', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Androgen Receptor agonist', 'linkedDiseasesDrug_string': "Erectile Dysfunction (EFO_0004234), Cancer (MONDO_0004992), Hip Fracture (EFO_0003964), Coronary Artery Disease (EFO_0001645), Multiple Sclerosis (MONDO_0005301), Obesity (EFO_0001073), Aids (EFO_0000765), Hypogonadotropic Hypogonadism (MONDO_0018555), Klinefelter'S Syndrome (EFO_1001006), Aging (GO_0007568), Anorexia Nervosa (MONDO_0005351), Prostate Carcinoma (EFO_0001663), Spinal Cord Injury (EFO_1001919), Orchitis (EFO_1001078), Polycystic Ovary Syndrome (EFO_0000660), Prostate Cancer (MONDO_0008315), Cerebral Arterial Disease (EFO_1000859), Growth Delay (HP_0001510), Muscular Disease (EFO_0002970), Hypogonadotropic Hypogonadism (HP_0000044), Sexual Dysfunction (EFO_0004714), Hypogonadism (MONDO_0002146), Insulin Resistance (EFO_0002614), Abnormality Of Connective Tissue (HP_0003549), Sarcopenia (EFO_1000653), Menopause (EFO_0003922), Infertility (EFO_0000545), Chronic Kidney Disease (EFO_0003884), Kallmann Syndrome (MONDO_0018800), Testicular Carcinoma (EFO_0005088), Heart Failure (EFO_0003144), Metastatic Prostate Cancer (EFO_0000196), Metabolic Syndrome (EFO_0000195), Dyspareunia (HP_0030016), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145), Genetic Disorder Of Sex Development (Orphanet_325690)", 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1972, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.206 | Q22 | What is Multaq? | Multaq, also known generically as Dronedarone Hydrochloride, was approved by the FDA in 2009 to treat atrial fibrillation. It is a small molecule therapy that acts as a(n) blocker. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%multaq%" OR LOWER(tradeNames_string) LIKE "%multaq%" OR LOWER(drugSynonyms_string) LIKE "%multaq%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3872', 'tradeNames_string': 'Multaq', 'drugName': 'Dronedarone Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Voltage-gated L-type calcium channel blocker', 'linkedDiseasesDrug_string': 'Atrial Fibrillation (EFO_0000275)', 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001), HCN4 (ENSG00000138622), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), KCNJ2 (ENSG00000123700)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2009, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3873', 'tradeNames_string': 'Multaq', 'drugName': 'Dronedarone Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker', 'linkedDiseasesDrug_string': 'Atrial Fibrillation (EFO_0000275)', 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001), HCN4 (ENSG00000138622), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), KCNJ2 (ENSG00000123700)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2009, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3874', 'tradeNames_string': 'Multaq', 'drugName': 'Dronedarone Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Sodium channel alpha subunit blocker', 'linkedDiseasesDrug_string': 'Atrial Fibrillation (EFO_0000275)', 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001), HCN4 (ENSG00000138622), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), KCNJ2 (ENSG00000123700)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2009, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3875', 'tradeNames_string': 'Multaq', 'drugName': 'Dronedarone Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Inward rectifier potassium channel 2 blocker', 'linkedDiseasesDrug_string': 'Atrial Fibrillation (EFO_0000275)', 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001), HCN4 (ENSG00000138622), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), KCNJ2 (ENSG00000123700)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2009, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.199 | Q22 | What is Docetaxel? | The drug Docetaxel was approved by the FDA in 1996 to treat breast carcinoma, cancer, neoplasm, non-small cell lung carcinoma, breast neoplasm, and breast cancer. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%docetaxel%" OR LOWER(tradeNames_string) LIKE "%docetaxel%" OR LOWER(drugSynonyms_string) LIKE "%docetaxel%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1267', 'tradeNames_string': '', 'drugName': 'Docetaxel', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tubulin inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Multiple Myeloma (EFO_0001378), Malignant Colon Neoplasm (MONDO_0021063), Cervical Adenocarcinoma (EFO_0001416), Inflammatory Breast Carcinoma (EFO_1000984), Testicular Neoplasm (EFO_0004281), Lung Adenocarcinoma (EFO_0000571), Urinary Bladder Carcinoma (MONDO_0004986), Pharynx Cancer (EFO_0005577), Malignant Tumor Of Neck (MONDO_0021310), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Carcinoma (EFO_0000313), Breast Ductal Carcinoma In Situ (EFO_0000432), Endometrial Neoplasm (EFO_0004230), Liver Cancer (MONDO_0002691), Cervical Cancer (MONDO_0002974), Osteosarcoma (EFO_0000637), Ewing Sarcoma (EFO_0000174), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Leiomyosarcoma (EFO_0000564), Transitional Cell Carcinoma (EFO_1000601), Thyroid Gland Undifferentiated (Anaplastic) Carcinoma (EFO_1000595), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145), Cancer (MONDO_0004992), Gastrointestinal Stromal Tumor (MONDO_0011719), Squamous Cell Lung Carcinoma (EFO_0000708), Male Reproductive Organ Cancer (EFO_0007355), Vaginal Cancer (MONDO_0001402), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Prostate Carcinoma (EFO_0001663), Neuroendocrine Carcinoma (MONDO_0002120), Hepatocellular Carcinoma (EFO_0000182), Uterine Neoplasm (EFO_0003859), Gastric Adenocarcinoma (EFO_0000503), Gastric Carcinoma (EFO_0000178), Metastasis (EFO_0009708), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Oropharynx Cancer (EFO_1001931), Triple-Negative Breast Cancer (EFO_0005537), Salivary Gland Cancer (MONDO_0004669), Laryngeal Neoplasm (EFO_0003817), Urogenital Neoplasm (EFO_0003863), Esophageal Squamous Cell Carcinoma (EFO_0005922), Non-Small Cell Lung Carcinoma (EFO_0003060), Head And Neck Carcinoma (MONDO_0002038), Chemotherapy-Induced Nausea And Vomiting (EFO_0006911), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Urothelial Carcinoma (EFO_0008528), Esophageal Carcinoma (EFO_0002916), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Gastrointestinal Disease (EFO_0010282), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Tonsil Cancer (EFO_1001214), Lymphoma (EFO_0000574), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Biliary Tract Cancer (MONDO_0003060), Paranasal Sinus Neoplasm (EFO_0003866), Penile Cancer (MONDO_0001325), Pancreatic Carcinoma (EFO_0002618), Cachexia (HP_0004326), Colorectal Cancer (MONDO_0005575), Peritoneum Cancer (MONDO_0002087), Allergic Disease (MONDO_0005271), Biliary Tract Neoplasm (EFO_0003891), Chronic Myeloproliferative Disorder (EFO_0002428), Ovarian Serous Cystadenocarcinoma (EFO_1000043), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Adenocarcinoma (EFO_0000228), Uterine Carcinosarcoma (EFO_1000613), Testicular Carcinoma (EFO_0005088), Metastatic Prostate Cancer (EFO_0000196), Sarcoma (EFO_0000691), Synovial Sarcoma (EFO_0001376), Laryngeal Carcinoma (MONDO_0002358), Stomach Neoplasm (EFO_0003897), Anorexia (HP_0002039), Oral Cavity Cancer (EFO_0005570), Neoplasm Of Esophagus (MONDO_0021355), Peritoneal Neoplasm (EFO_1001100), Metastatic Melanoma (EFO_0002617), Endometrial Cancer (MONDO_0011962), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Vulva Cancer (MONDO_0001528), Prostate Cancer (MONDO_0008315), Neutropenia (MONDO_0001475), Male Breast Carcinoma (EFO_0006861), Oral Squamous Cell Carcinoma (EFO_0000199), Urethra Cancer (MONDO_0004192), Salivary Gland Carcinoma (MONDO_0000521), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Lung Neoplasm (MONDO_0021117), Kidney Neoplasm (EFO_0003865), Endometrioid Carcinoma (EFO_0000466), Ovarian Neoplasm (EFO_0003893), Anal Carcinoma (MONDO_0003199), Head And Neck Malignant Neoplasia (EFO_0006859), Mediastinal Cancer (EFO_0007362), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Nasopharyngeal Neoplasm (EFO_0004252), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Fatigue (HP_0012378), Pancreatic Neoplasm (EFO_0003860), Esophageal Cancer (MONDO_0007576)', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1996, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2177', 'tradeNames_string': 'Docefrez, Docetaxel, Taxceus, Taxotere', 'drugName': 'Docetaxel', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tubulin inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Multiple Myeloma (EFO_0001378), Malignant Colon Neoplasm (MONDO_0021063), Cervical Adenocarcinoma (EFO_0001416), Inflammatory Breast Carcinoma (EFO_1000984), Testicular Neoplasm (EFO_0004281), Lung Adenocarcinoma (EFO_0000571), Urinary Bladder Carcinoma (MONDO_0004986), Pharynx Cancer (EFO_0005577), Malignant Tumor Of Neck (MONDO_0021310), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Carcinoma (EFO_0000313), Breast Ductal Carcinoma In Situ (EFO_0000432), Endometrial Neoplasm (EFO_0004230), Liver Cancer (MONDO_0002691), Cervical Cancer (MONDO_0002974), Osteosarcoma (EFO_0000637), Ewing Sarcoma (EFO_0000174), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Leiomyosarcoma (EFO_0000564), Transitional Cell Carcinoma (EFO_1000601), Thyroid Gland Undifferentiated (Anaplastic) Carcinoma (EFO_1000595), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145), Cancer (MONDO_0004992), Gastrointestinal Stromal Tumor (MONDO_0011719), Squamous Cell Lung Carcinoma (EFO_0000708), Male Reproductive Organ Cancer (EFO_0007355), Vaginal Cancer (MONDO_0001402), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Prostate Carcinoma (EFO_0001663), Neuroendocrine Carcinoma (MONDO_0002120), Hepatocellular Carcinoma (EFO_0000182), Uterine Neoplasm (EFO_0003859), Gastric Adenocarcinoma (EFO_0000503), Gastric Carcinoma (EFO_0000178), Metastasis (EFO_0009708), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Oropharynx Cancer (EFO_1001931), Triple-Negative Breast Cancer (EFO_0005537), Salivary Gland Cancer (MONDO_0004669), Laryngeal Neoplasm (EFO_0003817), Urogenital Neoplasm (EFO_0003863), Esophageal Squamous Cell Carcinoma (EFO_0005922), Non-Small Cell Lung Carcinoma (EFO_0003060), Head And Neck Carcinoma (MONDO_0002038), Chemotherapy-Induced Nausea And Vomiting (EFO_0006911), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Urothelial Carcinoma (EFO_0008528), Esophageal Carcinoma (EFO_0002916), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Gastrointestinal Disease (EFO_0010282), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Tonsil Cancer (EFO_1001214), Lymphoma (EFO_0000574), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Biliary Tract Cancer (MONDO_0003060), Paranasal Sinus Neoplasm (EFO_0003866), Penile Cancer (MONDO_0001325), Pancreatic Carcinoma (EFO_0002618), Cachexia (HP_0004326), Colorectal Cancer (MONDO_0005575), Peritoneum Cancer (MONDO_0002087), Allergic Disease (MONDO_0005271), Biliary Tract Neoplasm (EFO_0003891), Chronic Myeloproliferative Disorder (EFO_0002428), Ovarian Serous Cystadenocarcinoma (EFO_1000043), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Adenocarcinoma (EFO_0000228), Uterine Carcinosarcoma (EFO_1000613), Testicular Carcinoma (EFO_0005088), Metastatic Prostate Cancer (EFO_0000196), Sarcoma (EFO_0000691), Synovial Sarcoma (EFO_0001376), Laryngeal Carcinoma (MONDO_0002358), Stomach Neoplasm (EFO_0003897), Anorexia (HP_0002039), Oral Cavity Cancer (EFO_0005570), Neoplasm Of Esophagus (MONDO_0021355), Peritoneal Neoplasm (EFO_1001100), Metastatic Melanoma (EFO_0002617), Endometrial Cancer (MONDO_0011962), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Vulva Cancer (MONDO_0001528), Prostate Cancer (MONDO_0008315), Neutropenia (MONDO_0001475), Male Breast Carcinoma (EFO_0006861), Oral Squamous Cell Carcinoma (EFO_0000199), Urethra Cancer (MONDO_0004192), Salivary Gland Carcinoma (MONDO_0000521), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Lung Neoplasm (MONDO_0021117), Kidney Neoplasm (EFO_0003865), Endometrioid Carcinoma (EFO_0000466), Ovarian Neoplasm (EFO_0003893), Anal Carcinoma (MONDO_0003199), Head And Neck Malignant Neoplasia (EFO_0006859), Mediastinal Cancer (EFO_0007362), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Nasopharyngeal Neoplasm (EFO_0004252), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Fatigue (HP_0012378), Pancreatic Neoplasm (EFO_0003860), Esophageal Cancer (MONDO_0007576)', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1996, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.667 | Q22 | What is Tyvaso Dpi? | Tyvaso Dpi, also known generically as Treprostinil, was approved by the FDA in 2002 to treat Recurrent thrombophlebitis, pulmonary arterial hypertension, and pulmonary hypertension. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tyvaso dpi%" OR LOWER(tradeNames_string) LIKE "%tyvaso dpi%" OR LOWER(drugSynonyms_string) LIKE "%tyvaso dpi%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1758', 'tradeNames_string': 'Remodulin, Tyvaso, Tyvaso dpi', 'drugName': 'Treprostinil', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Prostanoid IP receptor agonist', 'linkedDiseasesDrug_string': 'Recurrent Thrombophlebitis (HP_0004419), Pulmonary Hypertension (MONDO_0005149), Primary Pulmonary Hypertension (MONDO_0001999), Ischemia Reperfusion Injury (EFO_0002687), Raynaud Disease (EFO_1001145), Chronic Obstructive Pulmonary Disease (EFO_0000341), Adult Acute Respiratory Distress Syndrome (MONDO_0100130), Persistent Fetal Circulation Syndrome (EFO_1001103), Peripheral Vascular Disease (EFO_0003875), Pulmonary Arterial Hypertension (EFO_0001361), Diabetic Foot (EFO_1001459), Type 1 Diabetes Mellitus (MONDO_0005147), Idiopathic Pulmonary Fibrosis (EFO_0000768), Systemic Scleroderma (EFO_0000717), Ischemia (EFO_0000556), Congenital Heart Disease (EFO_0005207)', 'newLinkedTargets_string': 'PTGIR (ENSG00000160013)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2002, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.333 | Q22 | What is Acular Ls? | Acular Ls, also known generically as Ketorolac Tromethamine, was approved by the FDA in 1989 to treat Ocular pain, inflammation, pain, and cataract. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%acular ls%" OR LOWER(tradeNames_string) LIKE "%acular ls%" OR LOWER(drugSynonyms_string) LIKE "%acular ls%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2258', 'tradeNames_string': 'Acular, Acular ls, Acular preservative free, Acuvail, Ketorolac tromethamine, Sprix, Toradol', 'drugName': 'Ketorolac Tromethamine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Cyclooxygenase inhibitor', 'linkedDiseasesDrug_string': 'Heart Disease (EFO_0003777), Cerebral Arterial Disease (EFO_1000859), Pulpitis (EFO_1001139), Cataract (MONDO_0005129), Migraine Disorder (MONDO_0005277), Renal Colic (EFO_1001412), Pain (EFO_0003843), Ocular Pain (HP_0200026), Back Pain (HP_0003418), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Inflammation (MP_0001845), Allergic Rhinitis (EFO_0005854), Shoulder Impingement Syndrome (EFO_1001178), Nephrolithiasis (EFO_0004253), Macular Retinal Edema (MONDO_0003005)', 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1989, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.405 | Q22 | What is Apriso? | Apriso, also known generically as Mesalamine, was approved by the FDA in 1987 to treat ulcerative colitis and proctitis. It is a small molecule therapy that acts as a(n) agonist and inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%apriso%" OR LOWER(tradeNames_string) LIKE "%apriso%" OR LOWER(drugSynonyms_string) LIKE "%apriso%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3359', 'tradeNames_string': 'Vaprisol', 'drugName': 'Conivaptan Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Vasopressin V2 receptor antagonist', 'linkedDiseasesDrug_string': 'Liver Disease (EFO_0001421), Heart Failure (EFO_0003144), Hyponatremia (HP_0002902)', 'newLinkedTargets_string': 'AVPR1A (ENSG00000166148), AVPR2 (ENSG00000126895)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2005, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3360', 'tradeNames_string': 'Vaprisol', 'drugName': 'Conivaptan Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Vasopressin V1a receptor antagonist', 'linkedDiseasesDrug_string': 'Liver Disease (EFO_0001421), Heart Failure (EFO_0003144), Hyponatremia (HP_0002902)', 'newLinkedTargets_string': 'AVPR1A (ENSG00000166148), AVPR2 (ENSG00000126895)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2005, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_6047', 'tradeNames_string': 'Apriso, Asacol, Asacol hd, Canasa, Coltec ec, Delzicol, Ipocol, Lialda, Mesalamine, Mesren mr, Mezavant xl, Octasa, Pentasa, Pentasa sr, Rowasa, Salofalk, Sfrowasa', 'drugName': 'Mesalamine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Peroxisome proliferator-activated receptor gamma agonist', 'linkedDiseasesDrug_string': "Lynch Syndrome (MONDO_0005835), Collagenous Colitis (EFO_1001293), Proctitis (EFO_0005628), Crohn'S Disease (EFO_0000384), Berylliosis (EFO_0007168), Hiv Infection (EFO_0000764), Colorectal Adenoma (EFO_0005406), Colitis (EFO_0003872), Irritable Bowel Syndrome (EFO_0000555), Colorectal Carcinoma (EFO_1001951), Eosinophilic Esophagitis (EFO_0004232), Colonic Diverticula (HP_0002253), Diverticulitis (EFO_1001460), Lymphocytic Colitis (EFO_1001294), Malnutrition (EFO_0008572), Ulcerative Colitis (EFO_0000729), Diverticular Disease (EFO_0009959)", 'newLinkedTargets_string': 'PPARG (ENSG00000132170), ALOX5 (ENSG00000012779), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1987, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_6048', 'tradeNames_string': 'Apriso, Asacol, Asacol hd, Canasa, Coltec ec, Delzicol, Ipocol, Lialda, Mesalamine, Mesren mr, Mezavant xl, Octasa, Pentasa, Pentasa sr, Rowasa, Salofalk, Sfrowasa', 'drugName': 'Mesalamine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Arachidonate 5-lipoxygenase inhibitor', 'linkedDiseasesDrug_string': "Lynch Syndrome (MONDO_0005835), Collagenous Colitis (EFO_1001293), Proctitis (EFO_0005628), Crohn'S Disease (EFO_0000384), Berylliosis (EFO_0007168), Hiv Infection (EFO_0000764), Colorectal Adenoma (EFO_0005406), Colitis (EFO_0003872), Irritable Bowel Syndrome (EFO_0000555), Colorectal Carcinoma (EFO_1001951), Eosinophilic Esophagitis (EFO_0004232), Colonic Diverticula (HP_0002253), Diverticulitis (EFO_1001460), Lymphocytic Colitis (EFO_1001294), Malnutrition (EFO_0008572), Ulcerative Colitis (EFO_0000729), Diverticular Disease (EFO_0009959)", 'newLinkedTargets_string': 'PPARG (ENSG00000132170), ALOX5 (ENSG00000012779), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1987, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_6049', 'tradeNames_string': 'Apriso, Asacol, Asacol hd, Canasa, Coltec ec, Delzicol, Ipocol, Lialda, Mesalamine, Mesren mr, Mezavant xl, Octasa, Pentasa, Pentasa sr, Rowasa, Salofalk, Sfrowasa', 'drugName': 'Mesalamine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Cyclooxygenase inhibitor', 'linkedDiseasesDrug_string': "Lynch Syndrome (MONDO_0005835), Collagenous Colitis (EFO_1001293), Proctitis (EFO_0005628), Crohn'S Disease (EFO_0000384), Berylliosis (EFO_0007168), Hiv Infection (EFO_0000764), Colorectal Adenoma (EFO_0005406), Colitis (EFO_0003872), Irritable Bowel Syndrome (EFO_0000555), Colorectal Carcinoma (EFO_1001951), Eosinophilic Esophagitis (EFO_0004232), Colonic Diverticula (HP_0002253), Diverticulitis (EFO_1001460), Lymphocytic Colitis (EFO_1001294), Malnutrition (EFO_0008572), Ulcerative Colitis (EFO_0000729), Diverticular Disease (EFO_0009959)", 'newLinkedTargets_string': 'PPARG (ENSG00000132170), ALOX5 (ENSG00000012779), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1987, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.96 | Q22 | What is Alunbrig? | Alunbrig, also known generically as Brigatinib, was approved by the FDA in 2017 to treat neoplasm and non-small cell lung carcinoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%alunbrig%" OR LOWER(tradeNames_string) LIKE "%alunbrig%" OR LOWER(drugSynonyms_string) LIKE "%alunbrig%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1566', 'tradeNames_string': 'Alunbrig', 'drugName': 'Brigatinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'ALK tyrosine kinase receptor inhibitor', 'linkedDiseasesDrug_string': 'Anaplastic Large Cell Lymphoma (EFO_0003032), Non-Small Cell Lung Carcinoma (EFO_0003060), Neoplasm (EFO_0000616)', 'newLinkedTargets_string': 'EGFR (ENSG00000146648), ALK (ENSG00000171094)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2017, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1567', 'tradeNames_string': 'Alunbrig', 'drugName': 'Brigatinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Epidermal growth factor receptor erbB1 inhibitor', 'linkedDiseasesDrug_string': 'Anaplastic Large Cell Lymphoma (EFO_0003032), Non-Small Cell Lung Carcinoma (EFO_0003060), Neoplasm (EFO_0000616)', 'newLinkedTargets_string': 'EGFR (ENSG00000146648), ALK (ENSG00000171094)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2017, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.594 | Q22 | What is Lumakras? | Lumakras, also known generically as Sotorasib, was approved by the FDA in 2021 to treat neoplasm and non-small cell lung carcinoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lumakras%" OR LOWER(tradeNames_string) LIKE "%lumakras%" OR LOWER(drugSynonyms_string) LIKE "%lumakras%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1834', 'tradeNames_string': 'Lumakras', 'drugName': 'Sotorasib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'GTPase KRas inhibitor', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Lung Adenocarcinoma (EFO_0000571), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Liver Disease (EFO_0001421), Non-Small Cell Lung Carcinoma (EFO_0003060), Colorectal Adenocarcinoma (EFO_0000365)', 'newLinkedTargets_string': 'KRAS (ENSG00000133703)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.298 | Q22 | What is Intuniv? | Intuniv, also known generically as Guanfacine, was approved by the FDA in 1986 to treat hypertension. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%intuniv%" OR LOWER(tradeNames_string) LIKE "%intuniv%" OR LOWER(drugSynonyms_string) LIKE "%intuniv%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5983', 'tradeNames_string': 'Intuniv', 'drugName': 'Guanfacine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Adrenergic receptor alpha-2 agonist', 'linkedDiseasesDrug_string': 'Post-Traumatic Stress Disorder (EFO_0001358), Alzheimer Disease (MONDO_0004975), Smoking Cessation (EFO_0004319), Drug Dependence (EFO_0003890), Nicotine Dependence (EFO_0003768), Stroke (EFO_0000712), Tourette Syndrome (EFO_0004895), Hypertension (EFO_0000537), Delirium (EFO_0009267), Schizotypal Personality Disorder (MONDO_0001087), Attention Deficit Hyperactivity Disorder (EFO_0003888), Cannabis Dependence (EFO_0007191), Cocaine Dependence (EFO_0002610), Trigeminal Neuralgia (EFO_1001219), Alcohol Dependence (MONDO_0007079), Alcohol Drinking (EFO_0004329)', 'newLinkedTargets_string': 'ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA2B (ENSG00000274286)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1986, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4912', 'tradeNames_string': 'Akfen, Estulic, Guanfacine hydrochloride, Intuniv, Tenex', 'drugName': 'Guanfacine Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Adrenergic receptor alpha-2 agonist', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888), Hypertension (EFO_0000537)', 'newLinkedTargets_string': 'ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA2B (ENSG00000274286)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1986, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.269 | Q22 | What is Iluvien? | Iluvien, also known generically as Fluocinolone Acetonide, was approved by the FDA in 1963 to treat atopic eczema, psoriasis, skin disease, freckles, infectious disease, eye inflammation, hemorrhoid, seborrheic dermatitis, uveitis, and macular retinal edema. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%iluvien%" OR LOWER(tradeNames_string) LIKE "%iluvien%" OR LOWER(drugSynonyms_string) LIKE "%iluvien%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4767', 'tradeNames_string': 'Capex, Derma-smoothe/fs, Dermotic, Fluocet, Fluocinolone acetonide, Fluonid, Fluotrex, Fs shampoo, Iluvien, Retisert, Synalar, Synalar fte, Synalar-c, Synalar-hp, Synalar-n, Synandone, Yutiq', 'drugName': 'Fluocinolone Acetonide', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucocorticoid receptor agonist', 'linkedDiseasesDrug_string': 'Uveitis (EFO_1001231), Psoriasis (EFO_0000676), Macular Degeneration (EFO_0009606), Hemorrhoid (EFO_0009552), Infectious Disease (EFO_0005741), Atopic Eczema (EFO_0000274), Eye Inflammation (EFO_0005752), Freckles (EFO_0003963), Otitis Externa (EFO_0009560), Seborrheic Dermatitis (EFO_1000764), Skin Disease (EFO_0000701), Posterior Uveitis (EFO_1001119), Glaucoma (MONDO_0005041), Retinopathy (EFO_0003839), Age-Related Macular Degeneration (EFO_0001365), Macular Retinal Edema (MONDO_0003005)', 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1963, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.381 | Q22 | What is Juxtapid? | Juxtapid, also known generically as Lomitapide Mesylate, was approved by the FDA in 2012 to treat Hypercholesterolemia, familial hypercholesterolemia, and homozygous familial hypercholesterolemia. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%juxtapid%" OR LOWER(tradeNames_string) LIKE "%juxtapid%" OR LOWER(drugSynonyms_string) LIKE "%juxtapid%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3058', 'tradeNames_string': 'Juxtapid', 'drugName': 'Lomitapide Mesylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Microsomal triglyceride transfer protein inhibitor', 'linkedDiseasesDrug_string': 'Hyperlipidemia (MONDO_0021187), Homozygous Familial Hypercholesterolemia (MONDO_0018328), Familial Hypercholesterolemia (EFO_0004911), Hypercholesterolemia (HP_0003124)', 'newLinkedTargets_string': 'MTTP (ENSG00000138823), P4HB (ENSG00000185624)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.187 | Q22 | What is Dexilant Solutab? | Dexilant Solutab, also known generically as Dexlansoprazole, was approved by the FDA in 2009 to treat Peptic ulcer, Esophagitis, gastroesophageal reflux disease, duodenal ulcer, and gastric ulcer. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dexilant solutab%" OR LOWER(tradeNames_string) LIKE "%dexilant solutab%" OR LOWER(drugSynonyms_string) LIKE "%dexilant solutab%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_908', 'tradeNames_string': 'Dexilant, Dexilant solutab, Kapidex', 'drugName': 'Dexlansoprazole', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Potassium-transporting ATPase inhibitor', 'linkedDiseasesDrug_string': "Esophagitis (HP_0100633), Gastric Ulcer (EFO_0009454), Duodenal Ulcer (EFO_0004607), Peptic Esophagitis (EFO_1001095), Peptic Ulcer (HP_0004398), Barrett'S Esophagus (EFO_0000280), Gastroesophageal Reflux Disease (EFO_0003948)", 'newLinkedTargets_string': 'ATP4A (ENSG00000105675), ATP4B (ENSG00000186009)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2009, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.643 | Q22 | What is Aggrastat? | Aggrastat, also known generically as Tirofiban Hydrochloride, was approved by the FDA in 1998 to treat myocardial infarction. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%aggrastat%" OR LOWER(tradeNames_string) LIKE "%aggrastat%" OR LOWER(drugSynonyms_string) LIKE "%aggrastat%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2127', 'tradeNames_string': '', 'drugName': 'Tirofiban', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Integrin alpha-IIb/beta-3 inhibitor', 'linkedDiseasesDrug_string': 'Recurrent Thrombophlebitis (HP_0004419), Coronary Artery Disease (EFO_0001645), Ischemic Stroke (HP_0002140), Viral Pneumonia (EFO_0007541), Stroke (EFO_0000712), Covid-19 (MONDO_0100096), Myocardial Infarction (EFO_0000612), Respiratory Failure (EFO_0009686), Venous Thromboembolism (EFO_0004286), Acute Coronary Syndrome (EFO_0005672), Acute Myocardial Infarction (EFO_0008583), Renal Insufficiency (HP_0000083)', 'newLinkedTargets_string': 'ITGB3 (ENSG00000259207), ITGA2B (ENSG00000005961)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1998, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2897', 'tradeNames_string': 'Aggrastat', 'drugName': 'Tirofiban Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Integrin alpha-IIb/beta-3 inhibitor', 'linkedDiseasesDrug_string': 'Myocardial Infarction (EFO_0000612)', 'newLinkedTargets_string': 'ITGB3 (ENSG00000259207), ITGA2B (ENSG00000005961)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1998, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.519 | Q22 | What is Suprenza? | Suprenza, also known generically as Phentermine Hydrochloride, was approved by the FDA in 1973 to treat obesity. It is a small molecule therapy that acts as a(n) releasing agent. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%suprenza%" OR LOWER(tradeNames_string) LIKE "%suprenza%" OR LOWER(drugSynonyms_string) LIKE "%suprenza%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5704', 'tradeNames_string': 'Adipex-p, Fastin, Lomaira, Obestin-30, Oby-trim, Ona-mast, Phentermine hydrochloride, Suprenza, Tora, Wilpo', 'drugName': 'Phentermine Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'releasing agent', 'drugMechanismOfAction': 'Norepinephrine transporter releasing agent', 'linkedDiseasesDrug_string': 'Obesity (EFO_0001073)', 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1973, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.156 | Q22 | What is Mitigare? | Mitigare, also known generically as Colchicine, was approved by the FDA in 1961 to treat gout and familial Mediterranean fever. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mitigare%" OR LOWER(tradeNames_string) LIKE "%mitigare%" OR LOWER(drugSynonyms_string) LIKE "%mitigare%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4743', 'tradeNames_string': 'Colchicine, Colcrys, Gloperba, Mitigare', 'drugName': 'Colchicine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tubulin inhibitor', 'linkedDiseasesDrug_string': "Coronary Artery Disease (EFO_0001645), Non-St Elevation Myocardial Infarction (EFO_0008586), Behcet'S Syndrome (EFO_0003780), Covid-19 (MONDO_0100096), Vasculitis (EFO_0006803), St Elevation Myocardial Infarction (EFO_0008585), Lung Disease (EFO_0003818), Coronavirus Infectious Disease (EFO_0007224), Primary Biliary Cirrhosis (EFO_1001486), Atrial Fibrillation (EFO_0000275), Prostate Cancer (MONDO_0008315), Hypertension (EFO_0000537), Intracranial Hemorrhage (EFO_0000551), Aphthous Ulcer (EFO_0003938), Acute Coronary Syndrome (EFO_0005672), Cardiac Arrhythmia (EFO_0004269), Postpericardiotomy Syndrome (EFO_1001404), Cholangiocarcinoma (EFO_0005221), Familial Mediterranean Fever (MONDO_0018088), Asthma (MONDO_0004979), Viral Pneumonia (EFO_0007541), Proliferative Vitreoretinopathy (EFO_1001129), Myocardial Infarction (EFO_0000612), Chronic Hepatitis C Virus Infection (EFO_0004220), Gout (EFO_0004274), Heart Disease (EFO_0003777), Chronic Kidney Disease (EFO_0003884), Urogenital Neoplasm (EFO_0003863), Osteoarthritis (MONDO_0005178), Diabetic Nephropathy (EFO_0000401), Amyotrophic Lateral Sclerosis (MONDO_0004976), Neoplasm (EFO_0000616), Heart Failure (EFO_0003144), Pericarditis (EFO_0007427), Vascular Disease (EFO_0004264), Atherosclerosis (EFO_0003914), Severe Acute Respiratory Syndrome (EFO_0000694), Cirrhosis Of Liver (EFO_0001422)", 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1961, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.76 | Q22 | What is Qvar Redihaler? | Qvar Redihaler, also known generically as Beclomethasone Dipropionate, was approved by the FDA in 1976 to treat Nasal congestion, Airway obstruction, seasonal allergic rhinitis, allergic rhinitis, Rhinitis, Allergic, Perennial, and asthma. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%qvar redihaler%" OR LOWER(tradeNames_string) LIKE "%qvar redihaler%" OR LOWER(drugSynonyms_string) LIKE "%qvar redihaler%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5013', 'tradeNames_string': 'Aerobec 100, Aerobec 50, Aerobec fte 250, Asmabec clickhaler, Asmabec spacehaler, Beclazone 100, Beclazone 100 e-breathe, Beclazone 200, Beclazone 250, Beclazone 250 e-breathe, Beclazone 50, Beclazone 50 e-breathe, Becloaqua 50, Becloforte, Becloforte e-breathe, Becloforte integra, Becloforte-vm, Beclomet diprop, Beclomet hayfever, Beclomist, Beclotaide, Beclovent, Becodisks, Beconase, Beconase aq, Becotide, Becotide 100, Becotide 100 e-breathe, Becotide 200, Becotide 50, Becotide 50 e-breathe, Clenil modulite, Clipper, Filair 100, Filair 50, Filair fte, Fostair, Fostair nexthaler, Nasobec aq, Nasobec hayfever, Propaderm, Propaderm fte, Propaderm-a, Propaderm-c, Pulvinal beclomet, Qnasl, Qvar 100, Qvar 100 e-breathe, Qvar 40, Qvar 50, Qvar 50 e-breathe, Qvar 80, Qvar redihaler, Rino clenil, Vancenase, Vancenase aq, Vancenase pockethaler, Vanceril, Vanceril double strength, Ventide, Vivabec, Zonivent aquanasal', 'drugName': 'Beclomethasone Dipropionate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucocorticoid receptor agonist', 'linkedDiseasesDrug_string': 'Infection (EFO_0000544), Graft Versus Host Disease (MONDO_0013730), Covid-19 (MONDO_0100096), Allergic Rhinitis (EFO_0005854), Idiopathic Pulmonary Fibrosis (EFO_0000768), Seasonal Allergic Rhinitis (EFO_0003956), Acute Graft Vs. Host Disease (EFO_0004599), Nasal Cavity Polyp (EFO_1000391), Sinusitis (EFO_0007486), Asthma (MONDO_0004979), Small Cell Lung Carcinoma (EFO_0000702), Bronchiectasis (HP_0002110), Rhinitis, Allergic, Perennial (EFO_1001417), Chronic Obstructive Pulmonary Disease (EFO_0000341), Airway Obstruction (HP_0006536), Nasal Congestion (HP_0001742), Croup (EFO_0007227), Newborn Respiratory Distress Syndrome (EFO_1000644), Enteritis (MONDO_0043579), Folliculitis (EFO_1000702), Eosinophilic Esophagitis (EFO_0004232), Bronchopulmonary Dysplasia (MONDO_0019091)', 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1976, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.338 | Q22 | What is Tykerb? | Tykerb, also known generically as Lapatinib Ditosylate, was approved by the FDA in 2007 to treat breast carcinoma, breast neoplasm, and breast cancer. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tykerb%" OR LOWER(tradeNames_string) LIKE "%tykerb%" OR LOWER(drugSynonyms_string) LIKE "%tykerb%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2160', 'tradeNames_string': 'Tykerb', 'drugName': 'Lapatinib Ditosylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Epidermal growth factor receptor erbB1 inhibitor', 'linkedDiseasesDrug_string': 'Central Nervous System Neoplasm (EFO_1000158), Gliosarcoma (EFO_1001465), Pancreatic Carcinoma (EFO_0002618), Head And Neck Malignant Neoplasia (EFO_0006859), Prostate Cancer (MONDO_0008315), Hypopharyngeal Carcinoma (EFO_0002938), Urinary Bladder Carcinoma (MONDO_0004986), Neoplasm (EFO_0000616), Breast Cancer (MONDO_0007254), Urinary Bladder Cancer (MONDO_0001187), Thyroid Carcinoma (EFO_0002892), Breast Neoplasm (EFO_0003869), Lymphoma (EFO_0000574), Male Breast Carcinoma (EFO_0006861), Oropharyngeal Carcinoma (MONDO_0044926), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Endometrial Carcinoma (EFO_1001512), Breast Carcinoma (EFO_0000305)', 'newLinkedTargets_string': 'EGFR (ENSG00000146648), ERBB2 (ENSG00000141736)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2007, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2161', 'tradeNames_string': 'Tykerb', 'drugName': 'Lapatinib Ditosylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Receptor protein-tyrosine kinase erbB-2 inhibitor', 'linkedDiseasesDrug_string': 'Central Nervous System Neoplasm (EFO_1000158), Gliosarcoma (EFO_1001465), Pancreatic Carcinoma (EFO_0002618), Head And Neck Malignant Neoplasia (EFO_0006859), Prostate Cancer (MONDO_0008315), Hypopharyngeal Carcinoma (EFO_0002938), Urinary Bladder Carcinoma (MONDO_0004986), Neoplasm (EFO_0000616), Breast Cancer (MONDO_0007254), Urinary Bladder Cancer (MONDO_0001187), Thyroid Carcinoma (EFO_0002892), Breast Neoplasm (EFO_0003869), Lymphoma (EFO_0000574), Male Breast Carcinoma (EFO_0006861), Oropharyngeal Carcinoma (MONDO_0044926), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Endometrial Carcinoma (EFO_1001512), Breast Carcinoma (EFO_0000305)', 'newLinkedTargets_string': 'EGFR (ENSG00000146648), ERBB2 (ENSG00000141736)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2007, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.69 | Q22 | What is Ozobax? | Ozobax, also known generically as Baclofen, was approved by the FDA in 1977 to treat Spasticity, Rigidity, spinal cord disease, cerebral palsy, Spinal cord injury, multiple sclerosis, and brain injury. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ozobax%" OR LOWER(tradeNames_string) LIKE "%ozobax%" OR LOWER(drugSynonyms_string) LIKE "%ozobax%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3627', 'tradeNames_string': 'Baclofen, Baclospas-10, Fleqsuvy, Gablofen, Kemstro, Lioresal, Lioresal intrath, Lyflex, Lyvispah, Ozobax', 'drugName': 'Baclofen', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'GABA-B receptor agonist', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Cerebral Palsy (EFO_1000632), Spinal Cord Disease (EFO_0009488), Multiple Sclerosis (MONDO_0005301), Pain (EFO_0003843), Obesity (EFO_0001073), Spasticity (HP_0001257), Cannabis Dependence (EFO_0007191), Reproductive System Disease (EFO_0000512), Spinal Cord Injury (EFO_1001919), Charcot-Marie-Tooth Disease (MONDO_0015626), Hepatocellular Carcinoma (EFO_0000182), Nicotine Dependence (EFO_0003768), Fragile X Syndrome (MONDO_0010383), Cocaine Dependence (EFO_0002610), Alcohol Withdrawal (EFO_0004777), Drug Dependence (EFO_0003890), Rigidity (HP_0002063), Brain Injury (MONDO_0043510), Ataxia Telangiectasia (MONDO_0008840), Gastroesophageal Reflux Disease (EFO_0003948), Alcohol Dependence (MONDO_0007079), Alcoholic Liver Cirrhosis (EFO_1000802)', 'newLinkedTargets_string': 'GABBR1 (ENSG00000204681), GABBR2 (ENSG00000136928)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1977, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.622 | Q22 | What is Torisel? | Torisel, also known generically as Temsirolimus, was approved by the FDA in 2007 to treat cancer, clear cell renal carcinoma, neoplasm, and renal cell carcinoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%torisel%" OR LOWER(tradeNames_string) LIKE "%torisel%" OR LOWER(drugSynonyms_string) LIKE "%torisel%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5750', 'tradeNames_string': 'Torisel', 'drugName': 'Temsirolimus', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'FK506-binding protein 1A inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Neuroblastoma (EFO_0000621), Non-Hodgkins Lymphoma (EFO_0005952), Genital Neoplasm, Female (EFO_1001331), Somatostatinoma (EFO_1001187), Mixed Glioma (MONDO_0003268), Peripheral Arterial Disease (EFO_0004265), Oligodendroglioma (EFO_0000632), Malignant Colon Neoplasm (MONDO_0021063), Pancreatic Insulinoma (MONDO_0024677), Myelodysplastic Syndrome (EFO_0000198), Hepatoblastoma (EFO_1000292), Endometrial Cancer (MONDO_0011962), Chronic Myelogenous Leukemia (EFO_0000339), Ovarian Cancer (MONDO_0008170), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Breast Neoplasm (EFO_0003869), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Fallopian Tube Carcinoma (EFO_1000251), Prostate Cancer (MONDO_0008315), Mantle Cell Lymphoma (EFO_1001469), Embryonal Rhabdomyosarcoma (EFO_0000437), Breast Cancer (MONDO_0007254), Anaplastic Astrocytoma (EFO_0002499), Lymphoma (EFO_0000574), Male Breast Carcinoma (EFO_0006861), Acute Myeloid Leukemia (EFO_0000222), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Diffuse Large B-Cell Lymphoma (EFO_0000403), Urethra Cancer (MONDO_0004192), Metastasis (EFO_0009708), Endometrial Carcinoma (EFO_1001512), Central Nervous System Neoplasm (EFO_1000158), Anaplastic Oligodendroglioma (EFO_0002501), Small Cell Lung Carcinoma (EFO_0000702), Ganglioneuroblastoma (EFO_0000502), Clear Cell Renal Carcinoma (EFO_0000349), Alveolar Rhabdomyosarcoma (EFO_0000248), Renal Cell Carcinoma (EFO_0000681), Adenoma (EFO_0000232), Brain Neoplasm (EFO_0003833), Soft Tissue Sarcoma (EFO_1001968), Peritoneum Cancer (MONDO_0002087), Thyroid Cancer (MONDO_0002108), Rheumatoid Arthritis (EFO_0000685), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Endometrioid Carcinoma (EFO_0000466), Liver Cancer (MONDO_0002691), Cervical Cancer (MONDO_0002974), Pilocytic Astrocytoma (MONDO_0016691), Hodgkins Lymphoma (EFO_0000183), Osteosarcoma (EFO_0000637), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Subependymal Giant Cell Astrocytoma (MONDO_0016693), Leukemia (EFO_0000565), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Adenocarcinoma (EFO_0000228), Non-Small Cell Lung Carcinoma (EFO_0003060), Lung Cancer (MONDO_0008903), Fallopian Tube Cancer (MONDO_0002158), Kidney Cancer (MONDO_0002367), Squamous Cell Carcinoma (EFO_0000707), Melanoma (EFO_0000756), Ischemia (EFO_0000556), Sarcoma (EFO_0000691), Uterine Carcinosarcoma (EFO_1000613), Colorectal Adenocarcinoma (EFO_0000365), Glioblastoma Multiforme (EFO_0000519), Pancreatic Endocrine Carcinoma (EFO_0007416)', 'newLinkedTargets_string': 'FKBP1A (ENSG00000088832)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2007, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.191 | Q22 | What is Cambia? | Cambia, also known generically as Diclofenac Potassium, was approved by the FDA in 1993 to treat rheumatoid arthritis, pain, osteoarthritis, and migraine disorder. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cambia%" OR LOWER(tradeNames_string) LIKE "%cambia%" OR LOWER(drugSynonyms_string) LIKE "%cambia%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3122', 'tradeNames_string': 'Cambia, Voltaren, Voltaren Ophthalmic, Voltaren Xr, Zorvolex, Zorvolex capsules', 'drugName': 'Diclofenac', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Cyclooxygenase inhibitor', 'linkedDiseasesDrug_string': 'Toothache (EFO_0010072), Rheumatic Disease (EFO_0005755), Ankylosing Spondylitis (EFO_0003898), Hemorrhage (MP_0001914), Keratosis (EFO_1000720), Migraine Disorder (MONDO_0005277), Pain (EFO_0003843), Dysmenorrhea (HP_0100607), Otitis Externa (EFO_0009560), Injury (EFO_0000546), Pulmonary Embolism (EFO_0003827), Aging (GO_0007568), Breast Cancer (MONDO_0007254), Muscular Disease (EFO_0002970), Cataract (MONDO_0005129), Eye Inflammation (EFO_0005752), Osteoarthritis, Knee (EFO_0004616), Basal Cell Carcinoma (EFO_0004193), Periodontitis (EFO_0000649), Acute Pancreatitis (EFO_1000652), Sunburn (EFO_0003958), Anemia (Phenotype) (EFO_0004272), Osteoarthritis, Hip (EFO_1000786), Renal Colic (EFO_1001412), Infertility (EFO_0000545), Actinic Keratosis (EFO_0002496), Gastric Ulcer (EFO_0009454), Sprain (EFO_0009582), Inflammation (MP_0001845), Depressive Disorder (MONDO_0002050), Rheumatoid Arthritis (EFO_0000685), Carcinoma (EFO_0000313), Myalgia (HP_0003326), Gout (EFO_0004274), Osteoarthritis (MONDO_0005178), Pulpitis (EFO_1001139), Neoplasm (EFO_0000616), Arthralgia (HP_0002829), Urinary Bladder Cancer (MONDO_0001187), Chronic Pain (HP_0012532), Radiculopathy (MONDO_0002959), Mastodynia (EFO_1001366), Low Back Pain (HP_0003419)', 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1988, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5263', 'tradeNames_string': 'Cambia, Cataflam, Diclofenac potassium, Voltarol joint pain, Voltarol pain-eze, Voltarol pain-eze extra strgh, Voltarol rapid, Zipsor', 'drugName': 'Diclofenac Potassium', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Cyclooxygenase inhibitor', 'linkedDiseasesDrug_string': 'Toothache (EFO_0010072), Osteoarthritis (MONDO_0005178), Pulpitis (EFO_1001139), Pain (EFO_0003843), Migraine Disorder (MONDO_0005277), Dysmenorrhea (HP_0100607), Gastric Ulcer (EFO_0009454), Rheumatoid Arthritis (EFO_0000685)', 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1993, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.240 | Q22 | What is Vagifem? | Vagifem, also known generically as Estradiol, was approved by the FDA in 1975 to treat Premature ovarian insufficiency, Dyspareunia, and hypogonadism. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vagifem%" OR LOWER(tradeNames_string) LIKE "%vagifem%" OR LOWER(drugSynonyms_string) LIKE "%vagifem%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6277', 'tradeNames_string': 'Adgyn estro, Alora, Aquagen, Bedol, Climara, Climara Pro, Dermestril 100, Dermestril 25, Dermestril 50, Dermestril septem 25, Dermestril septem 50, Dermestril septem 75, Divigel, E-Cypionate, Elestrim, Elestrin, Elleste solo, Elleste solo mx 40, Elleste solo mx 80, Esclim, Estrace, Estraderm, Estraderm mx 100, Estraderm mx 25, Estraderm mx 50, Estraderm mx 75, Estraderm tts 100, Estraderm tts 25, Estraderm tts 50, Estradiol, Estrasorb, Estring, Estrogel, Evamist, Evorel 100, Evorel 25, Evorel 50, Evorel 75, Fematrix 40, Fematrix 80, Fempatch, Femseven 100, Femseven 50, Femseven 75, Gvnodiol, Gynodiol, Gynogen, Imvexxy, Innofem, Menorest 37.5, Menorest 50, Menorest 75, Menoring 50, Menostar, Minivelle, Oestradiol, Progynova ts, Sandrena, Vagifem, Vagifem 18, Vagifem 8, Vivelle, Vivelle-dot, Zumenon', 'drugName': 'Estradiol', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Estrogen receptor alpha agonist', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Multiple Sclerosis (MONDO_0005301), Pain (EFO_0003843), Covid-19 (MONDO_0100096), Uterine Fibroid (EFO_0000731), Migraine Disorder (MONDO_0005277), Dysmenorrhea (HP_0100607), Obesity (EFO_0001073), Dry Eye Syndrome (EFO_1000906), Atherosclerosis (EFO_0003914), Aging (GO_0007568), Anorexia Nervosa (MONDO_0005351), Hot Flashes (HP_0031217), Prostate Carcinoma (EFO_0001663), Breast Carcinoma (EFO_0000305), Myocardial Ischemia (EFO_1001375), Post-Traumatic Stress Disorder (EFO_0001358), Osteoporosis (EFO_0003882), Breast Neoplasm (EFO_0003869), Prostate Cancer (MONDO_0008315), Cerebral Arterial Disease (EFO_1000859), Breast Cancer (MONDO_0007254), Polycystic Ovary Syndrome (EFO_0000660), Osteopenia (HP_0000938), Postpartum Depression (EFO_0007453), Premature Ovarian Insufficiency (HP_0008209), Schizoaffective Disorder (EFO_0005411), Non-Alcoholic Steatohepatitis (EFO_1001249), Endometriosis (EFO_0001065), Amenorrhea (EFO_0010269), Sexual Dysfunction (EFO_0004714), Postmenopausal Atrophic Vaginitis (MONDO_0001410), Hypogonadism (MONDO_0002146), Turner Syndrome (MONDO_0019499), Menopause (EFO_0003922), Infertility (EFO_0000545), Urinary Tract Infection (EFO_0003103), Carcinoid Tumor (EFO_0004243), Hiv-1 Infection (EFO_0000180), Depressive Disorder (MONDO_0002050), Hiv Infection (EFO_0000764), Type 2 Diabetes Mellitus (MONDO_0005148), Atrophic Vaginitis (EFO_1001271), Blood Coagulation Disease (EFO_0009314), Atrophy (EFO_1000096), Bulimia Nervosa (EFO_0005204), Type 1 Diabetes Mellitus (MONDO_0005147), Dyspareunia (HP_0030016), Schizophrenia (MONDO_0005090), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145)', 'newLinkedTargets_string': 'ESR1 (ENSG00000091831)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1975, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.